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EVALUATION OF A SMALL MOLECULE AGONIST OF EPHA2 RECEPTOR 
TYROSINE KINASE  
AND  
COPALIC ACID ANALOGS AS PROSTATE CANCER THERAPEUTICS 
 
NETHRIE IDIPPILY 
 
ABSTRACT 
Project I: 
 
Chemotherapeutic drugs have many side effects that are undesirable and are highly toxic. 
Therefore, there is a growing need for the development of drugs with enhanced efficacy, 
specificity, and potency to provide cancer patients with a better prognosis. It was 
discovered that a member of the Receptor Tyrosine Kinase family, EphA2, may prove to 
be a viable target in developing anti-cancer agents. In the presence of its ligand, EphA2 
receptor is responsible for apoptotic and anti-migratory activity. However, in the absence 
of ligand, EphA2 is able to stimulate cell migration and therefore tumorigenic activity. 
These conflicting roles of EphA2 and the upregulation of this receptor that is seen in 
many cancers have provided a novel strategy in designing therapeutic agents. Therefore, 
small molecules can be used to stimulate ligand-dependent pathways of EphA2 that 
induce anti-migratory and anti-proliferative effects in cancer cells in order to inhibit 
metastasis and tumor progression. A small molecule, doxazosin, was identified as an 
EphA2 agonist in a recent study. It demonstrated positive results in that its actions were 
similar to those of the natural ligand. Subsequently, a library of compounds was 
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generated using doxazosin as the lead compound in order to improve its activity. These 
compounds were tested for their activity in stimulating EphA2 receptor. Two of them 
showed improved activity compared to doxazosin while mimicking a mechanism similar 
to the native ligand. The structure activity relationship of these derivatives, the in vitro 
mechanisms and pharmacokinetic profiles were also analyzed, which provides a basis for 
further optimization and subsequent in vivo studies of these compounds in the future. 
 
Project II:  
 
Copalic acid which is one of the diterpenoid acids in copaiba oil inhibited the chaperone 
function of -crystallin and heat shock protein 27 kDa (HSP27). It also showed potent 
activity in decreasing the level of an HSP27 client protein, androgen receptor (AR), 
which makes it useful in prostate cancer treatment. In order to develop potent drug 
candidates to decrease the AR level in prostate cancer cells, copalic acid analogs were 
synthesized. Using AR level as a readout 15 copalic acid analogs were screened, which 
showed that two of those compounds were much more potent than copalic acid. They 
inhibited AR positive prostate cancer cell growth in a dose-dependent manner. 
Furthermore, they also inhibited the chaperone activity of -crystallin. 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 PROJECT I: EVALUATION OF A SMALL MOLECULE AGONIST OF 
EPHA2 RECEPTOR TYROSINE KINASE 
 
1.1.1 Cancer 
 
 Considered the second leading cause of death in the United States, cancer is a 
disease that is still not fully comprehended today. According to the American Cancer 
Society, about 1.7 million new cases of cancer are projected to be diagnosed in 2018 and 
about 600,000 deaths are expected (Figure 1.1) (1). Cancer is a disease that springs from 
the uncontrollable growth of cells; the normal process of cell division and death is 
disturbed where the orderly progression is changed (5).  There are many types of cancers, 
such as lung, breast, prostate, colon, bladder, pancreatic, kidney, and brain cancer to 
name a few (10). There are many causes that give rise to cancer, such as an individual’s 
inherited genetic background or exposure to carcinogens. While cancer by itself is 
detrimental, metastasis that can arise poses greater risks. Metastasis is a process where 
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Figure 1.1: The number of estimated new cases of cancer diagnoses in each state in the 
US in 2018 (1).  
3 
 
cancer cells detach from the primary position and travel to other locations in the body 
through the blood circulation or the lymphatic systems and form new tumors (7). This 
stage of cancer is considered severe since it is not confined to one part of the body. In 
most cases, the probability of survival is decreased in patients that have metastatic cancer 
compared to those that have localized tumors (14).  
Several types of treatment exist for the different types of localized and metastatic 
cancers. The choice of treatment depends on factors such as the size and location of the 
primary cancer, the severity of metastasis, other medications that the patient is taking, 
and the general health of the patient (9). The most common types of treatment are 
chemotherapy, hormone therapy, thermal ablation, radiation therapy, and surgery (9). 
Depending on the severity of the cancer, these treatments are used individually or in 
combination with each other. Even though the treatment options have grown over the 
years, the side effects of these therapies are yet undesirable. A few of the most common 
side effects are nausea, vomiting, loss of appetite, alopecia, thrombocytopenia, diarrhea, 
constipation, and fatigue. In addition to these, long term effects can also arise within 
months or years after the treatment is completed (8). These include, but are not limited to, 
cardiac issues, changes in the endocrine system, lung problems, deterioration of bone and 
soft tissue, problems in the brain and spinal cord, and emotional problems such as post-
traumatic stress disorder (8). Due to these predicaments, the focus of cancer research has 
always been to improve drug efficacy and potency to provide successful treatments with 
minimal side effects. 
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1.1.2 Eph Receptor Tyrosine Kinase 
 
In the Receptor Tyrosine Kinase (RTK) family, erythropoietin-producing 
hepatocellular (Eph) receptors are the largest group (6). It is composed of fourteen 
receptor subtypes, EphA1-EphA8, EphA10, EphB1-EphB4, and EphB6, and their 
ligands, called ephrins that are further categorized into subclasses, ephrinA1-A5 and 
ephrinB1-B3 (13). Similar to other RTKs, the Eph receptors are involved in signal 
transduction and cell-cell communication which is important for processes such as 
embryonic morphogenesis, development and maintaining homeostasis in adult tissue (6).  
 The Eph receptor is a transmembrane protein with an extracellular region that has 
the ephrin ligand-binding domain and a region that expands to the cytoplasm which 
consists of the kinase domain (Figure 1.2) (6). The ephrin ligands that are attached to the 
surface of cells activate receptors that are expressed in the same cell or are released in 
order to activate receptors on neighboring cells (15). Upon ligand binding, the Eph 
receptors undergo endocytosis where they are internalized. Moreover, this binding can 
cause the oligomerization of both receptor-ligand and receptor-receptor complexes (6). 
The extent to which this process occurs depends on the cellular context which in turn can 
depend on the cytoskeleton of the cells (6). These interactions eventually lead to the 
phosphorylation of tyrosines which then allows the kinase domain to be active (6).  
 Upon entering the cell, the receptors continue to provide signals for different 
processes unless they are dephosphorylated, degraded, or directed towards the cell 
membrane. The Eph receptors regulate many of the same proteins that are involved in the 
downstream of other RTK members. Proteins such as nonreceptor tyrosine kinases of the  
5 
 
 
 
 
 
 
 
  
Figure 1.2: Diagram of Eph receptors’ structures with their 
ligands (6). 
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Src (proto-oncogene tyrosine-protein kinase) and Abl (tyrosine-protein kinase) groups 
that have an SH2 domain, and adaptors such as Nck and Crk are employed for inducing 
signaling (6). In addition, the most important downstream effectors are Akt, Rho, and Ras 
family members that are involved in the regulation of cell survival and proliferation. 
 Together with the ephrin-dependent pathways, Eph receptors are also known to 
have activities that are independent of ligand binding (6). These ephrin-independent 
pathways are known to have opposite effects compared to the ephrin-dependent 
pathways. This ligand-independent signaling is observed in many cancers where cell 
proliferation and migration is induced by an upregulation of the receptors and a decrease 
in ephrin ligand. One such Eph receptor that is being studied for its role in tumor 
progression is EphA2 (4). Elucidation of its mechanism may provide the basis for the 
development of a novel therapeutic target against cancer cells. 
 
1.1.3 EphA2  
 
 
A member of the Eph receptors, EphA2, which was known as epithelial cell 
kinase (Eck), is a 130 kDa glycoprotein receptor (4).  EphA2 is predominant in the 
nervous system in the embryonic developmental stage, angiogenesis, and contrary to the 
other Eph receptors, it can also be found in adult epithelial cells (15). Recent studies have 
reported that the overexpression of EphA2 in cancer cells lead to metastasis and poor 
prognosis (10). The seemingly contradictory roles of this receptor have been correlated 
with tumor progression and malignancy especially in cancers such as glioblastoma, 
breast, melanoma, and prostate carcinoma (4). Binding of the ligand, ephrin-A1, induces 
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effects that are suppressive, such as apoptosis and cell migration inhibition (10). This was 
observed in in vivo studies where administration of ephrin-A1 reduced the invasiveness 
of carcinoma xenografts (10). In the absence of ligand, however, EphA2 receptor is 
activated through phosphorylation by Akt which stimulates cell migration. 
Overexpression of EphA2 is generally associated with a decrease in ephrin-A1 ligand, 
therefore, the migration stimulatory effects are amplified in oncogenic cells (11). 
 
1.1.4 EphA2 in Cancer 
 
The ligand-independent mechanism of EphA2 mentioned above which is 
conjectured to be the dominant pathway in tumorigenesis prove that it is a viable 
candidate for the development of drug therapies against cancer. In a study conducted by 
Bingcheng Wang et al. it was discovered that EphA2 agonists may provide tumor 
inhibitory effects (10). Their hypothesis was that in cancer cells where the expression of 
natural ligand is decreased, a small molecule agonist may be able to activate EphA2 
receptor and promote tumor invasion suppressive effects (10). The screening of multiple 
commercially available compounds revealed that doxazosin activated EphA2 
substantially in a manner similar to ephrinA-1 (10). Doxazosin is an FDA approved drug, 
commonly known as Cardura®, which is being used for the treatment of hypertension 
and the improvement of urination in men suffering with benign prostate hyperplasia 
(Figure 1.3) (2,12). Its mechanism of action is to block 1-adrenoreceptor and thereby 
induce a decrease in the systemic vascular resistance (3). In cancer cells, however, it was  
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Figure 1.3: Structure of doxazosin. 
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confirmed that activation of EphA2 and its inhibitory effects were not due to indirect 
effects of the suppression of 1-adrenoreceptor by doxazosin (10). Additionally, it was 
discovered that doxazosin exhibited effects similar to those caused by ligand-binding; 
Binding of doxazosin resulted in the internalization and degradation of the receptor, and 
also Akt kinase pathways that are responsible for stimulation of tumor progression were 
inhibited (10).  
 
1.1.5 Our hypothesis 
 
Chemotherapeutic drugs have many side effects that are undesirable and are 
highly toxic. Therefore, there is a growing need for the development of drugs with 
enhanced efficacy, specificity, and potency in order to provide cancer patients with a 
better prognosis. Because of EphA2’s implications in a number of cancers it is a viable 
therapeutic target. Taking advantage of EphA2’s tumor suppressor functions that are 
caused by the binding of ligand provides a path for the establishment of a new therapeutic 
strategy. Since doxazosin was recently discovered to behave in a similar manner to an 
EphA2 agonist it can be used as a lead compound to generate more potent analogs. We 
hypothesize that these new compounds may demonstrate increased agonist activity 
compared to doxazosin thus leading to tumor suppressive activity. 
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1.2 PROJECT II: COPALIC ACID ANALOGS AS PROSTATE CANCER 
THERAPEUTICS 
 
1.2.1 Prostate cancer 
 
 Prostate cancer is the most common type of cancer among men in the United 
States. There are about 164,690 new cases and about 29,430 deaths reported in 2018 (21). 
It occurs in the prostate which is a small walnut-shaped gland that secreted prostate fluid 
which is a component of semen (3) (Figure 1.4). Among other cancers, prostate cancer is 
the second leading cause of death in men and occurs more in African-American men 
compared to Caucasian men (21). Nearly all prostate cancers are adenocarcinomas and 
the early stages do not present any symptoms (21). Advanced stages may have symptoms 
such as frequent urination, reduced flow of urine, trouble urinating, pain the pelvic 
region, blood is semen, and bone pain (14). Typically, prostate cancer grows slowly, 
however, some cancers may grow and spread rapidly (21). 
Although uncertain, it is speculated that prostate cancer starts as a pre-cancerous 
condition which is usually revealed with a prostate biopsy (21). In prostatic intraepithelial 
neoplasia (PIN) the cells are abnormal but do not appear to grow into the other parts of 
the prostate. This condition can be seen in men in their early 20s, but not all of them 
develop cancer (21). In the other condition, proliferative inflammatory atrophy (PIA), the 
cells look smaller than normal and there are signs of inflammation. It is speculated that 
this may lead to PIN or directly to prostate cancer (21).  
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Figure 1.4: Prostate gland is a small walnut-shaped gland located below 
the bladder in males (14). 
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 Several treatment options exist for prostate cancer which include surgery, 
radiation therapy (external beam therapy and prostate brachytherapy), focal therapy, 
hormonal therapy (androgen deprivation therapy), chemotherapy, immunotherapy, bone-
directed therapy, and the use of radiopharmaceuticals (5). Although these treatments may 
be successful at times complications such as urinary, erectile, and bowel dysfunction, 
fatigue, skin irritation, constipation, and loss of fertility, and resistance can occur (16). 
 
1.2.2 Androgen receptor 
 
 Androgen receptor (AR) belongs to the steroid and nuclear receptor superfamily 
and is a key mediator in prostate cancer (6). AR is primarily expressed in tissues of the 
prostate, skeletal muscle, liver, and the central nervous system (6). The functions of AR 
are determined by the binding of ligands, known as androgens, which lead to interactions 
with other proteins or DNA related to male physiology (6, 19). When bound by AR’s 
native ligands, 5-dihydrotestosterone (DHT) and testosterone, it leads to male sexual 
development and differentiation (19).  
 AR, a 110 kDa protein encoded by the AR gene located in the X chromosome, 
consists of three domains: N terminal domain (NTD), DNA binding domain (DBD), and 
the C terminal ligand binding domain (LBD) connected by a small hinge region (Figure 
1.5) (19). The NTD, which is encoded by exon 1, has a highly variable sequence and 
length of polyglutamine (CAG) and polyglycine (GGC) repeats (19). Structurally, the 
length of the polyglutamine repeats region seems to affect the folding of the NTD and it 
is essential for the NTD’s modulatory functions such as contacting the transcriptional  
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Figure 1.5: Organization of the AR gene (6).  
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machinery (11, 19). The DBD is a highly conserved cysteine-rich region in the receptor 
(19). Each monomer of DBD has two zinc fingers in the core, and each one consists of 
four cysteine residues that accommodates a zinc ion (19). The -helix of the N-terminal 
zinc finger of DBD directly interacts with the nucleotides in the response elements of the 
DNA (19). Even though many steroidal receptors share a common response element, the 
target specificity of AR stems from androgen response elements (AREs) which allows for 
specific AR activation (19).  
In the junction between the DBD and the hinge region is the nuclear localization 
signal (NLS) that is required for importation of AR into the nucleus (19). The large size 
of AR does not allow passive transport across the nuclear membrane and therefore needs 
to be actively transported (19). Studies have demonstrated that androgen binding 
promotes a transformation in the AR that exposes the NLS that allows for the binding to 
importin- in order to be imported into the nucleus (19). The hinge region is also 
essential for localization as well as binding to DNA and the interaction between NTD and 
LBD (19). The LBD is composed of 11 -helices and two anti-parallel -sheets (6). 
When a ligand binds, it induces a conformational change in the LBD that allows for the 
formation of an activation function 2 (AF2) regions which is important for the interaction 
between the amino and carboxyl termini (6). 
When free testosterone enters the cell, it is readily converted in to its more active 
metabolite, DHT, by the enzyme 5-reductase (Figure 1.6) (19). The binding of DHT to 
AR results in the release of chaperone proteins, such as heat shock protein 70 and 90 
which are responsible for the stability of the inactive AR. Once DHT binds, heat shock  
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Figure 1.6: AR signaling pathway (19).  
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protein 27 kDa (HSP27) regulates the stability, shuttling, and transactivation of AR (18). 
This also causes a conformational change that enables AR to bind to importin- so that it 
can be transported into the nucleus (19). Once inside the nucleus, AR dimers bind to 
AREs in the target genes’ promotor region such as prostate specific antigen (PSA) and 
transmembrane protease serine 2 (TMPRSS2). Subsequently, they recruit coregulatory 
proteins to promote transcription which lead to outcomes such as growth and survival 
(11, 19). 
Because of its central role in the development and differentiation of male 
physiology, AR is closely connected to prostate cancer. Similar to the normal prostate 
cells, cancer cells in the prostate require androgens for growth and survival (19). And the 
higher than normal proliferation rate is mediated through the AR pathway. Therefore, the 
rationale for treatment has been to control the latter which is initiated by suppressing 
androgens by castration, either surgically or chemically (19). However, most patients 
eventually develop resistance where they no longer respond to androgen deprivation 
therapy. In castration resistant prostate cancer (CRPC), the tumor cells continue to grow 
even though the circulating level of androgens is low. Five different mechanisms have 
been identified to describe what occurs in CRPC. The first possible mechanism is the 
amplification of AR in order to increase the sensitivity to the low levels of androgens (4). 
Moreover, mutations in the AR gene itself and/or 5-reductase (the enzyme that is 
responsible for the conversion of testosterone into DHT, which is a native ligand of AR) 
has also shown to contribute to the increased level of AR (4). A second mechanism is the 
role of co-activators and co-repressors of AR in stimulating transcriptional pathways (4). 
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The overexpression of these molecules has shown to be associated with tumor 
progression. CRPC may also emanate in the absence of ligands in what is known as an  
outlaw pathway (4). Various growth factors, cytokines, and kinase pathways can 
contribute to the increased signaling of AR thereby causing the cancer to progress (4).   
Another pathway is one that results from altered steroidogenesis; for example, 
androgen precursors produced from the adrenal gland such as dehydroepiandosterone 
(DHEA) can be converted into DHT through an alternate pathway (4). The fifth 
mechanism is via variants of AR which are generated typically without the C-terminal 
ligand binding domain (4).  Because of the resistance to the current treatment options 
there is a great need for the development of a therapeutic agent that has the ability to 
overcome resistance and provide a better prognosis for CRPC patients.  
 
1.2.3 Heat chock protein 27 kDa (HSP27) 
 
 Heat shock protein 27 kDa (HSP27), also known as HspB1, has implications in 
many cancers, including prostate cancer. It belongs to the highly conserved family of 
small heat shock proteins (HSPs) (8). HSPs are primarily recognized for their rapid 
protective response to stress (17). In the latter, the transcription of HSPs increase and 
post-translational modifications determine their functions that are required for the 
specific situation.  Even though the N-terminal is variable, all small HSPs share a highly 
conserved C-terminal, -crystallin domain (20). HSP27 is involved in several cellular 
protective functions such as refolding of damaged protein, inhibition of apoptosis, 
protection against oxidative stress, and regulation of the cytoskeleton (Figure 1.7) (8, 20).   
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Figure 1.7: Functions of HSP27 (20). 
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During cellular stress, oligomers of non-phosphorylatable HSP27 bind to eIF4G 
(eukaryotic translation initiation factor 4 G) thereby inhibiting cap-dependent protein 
translation (17). HSP27 also acts as a chaperone by binding to the misfolded proteins and 
transferring them to ATP-dependent chaperones or by leading to proteasomal degradation 
so that aggregation of misfolded proteins decreases (17). In contrast, when HSP27 is 
phosphorylated it acts as an anti-apoptotic molecule that can interfere with both the 
intrinsic and extrinsic apoptotic pathways (17).  In the intrinsic pathway, following 
different stimuli such as oxidative stress, hyperthermia, and cytotoxic agents, HSP27 may 
interact with both upstream and downstream of cytochrome c release by mitochondria 
(13). HSP27 interacts with phosphatidylinositol 3-kinase (PI3-K) which activates Akt 
which in turn phosphorylates Bax which prevents the formation of pores in the 
mitochondria and thereby prevents the release of cytochrome c (8). It is speculated that 
HSP27 may also interact directly with cytosolic cytochrome c and inhibit the activation 
of pro-caspase-9 (13). In the extrinsic pathway, apoptosis is initiated from the membrane 
receptors such as Fas receptor. When the ligand binds, Fas receptor interacts with Fas 
associated-death-domain protein (FADD) which in turn activates procaspase-8 and other 
downstream caspases and also regulates the interaction of Bax with mitochondria (8). 
Furthermore, Fas receptor may also interact with a protein known as Daxx whose 
translocation from the nucleus to the cytosol can induce apoptosis (8). Phosphorylated 
HSP27 may interact with Daxx and prevent its translocation which would then inhibit 
Daxx-dependent apoptotic activity (8).  
When exposed to oxidative stress, HSP27 acts as an antioxidant and increases the 
level of glutathione and iron in the cells in order to decrease the level of reactive oxygen 
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species (ROS). It also leads the oxidized proteins to the proteasome so that they can be 
degraded (2). HSP27 is a downstream effector of the p38 MAP kinase pathway (mitogen 
activated protein kinase pathway) that regulates the actin filament dynamics (7). 
Therefore, during stress, HSP27 is able to stabilize actin microfilaments by inhibiting F-
actin polymerization (7). 
In addition to its involvement in neurodegenerative and cardiovascular diseases, 
HSP27 was also found to play a role in many types of cancer such as prostate carcinoma, 
gastric, liver, breast, osteosarcoma, and lung cancer (20). The overexpression of HSP27 
leads to the proliferation, differentiation, and invasion of tumor cells (8). Since it is 
involved in the inhibition of apoptosis, high levels of HSP27 can result in defects in the 
apoptotic pathway directly or through its client proteins causing tumor progression (8). 
This indicates that HSP27 is a potential therapeutic target against cancer. 
 
1.2.4 Copaiba oil 
 
Copaiba oil is a popular medicine widely used for its anti-inflammatory, 
antimicrobial, antileishmanial, larvicidal, wound healing, antineoplastic, and 
antinoceptive properties. It is obtained from the trunk of the trees of the Copaifera genus 
which is native to the regions of Latin America and Western Africa (10).  Copaiba oil is 
administered topically or orally to relieve symptoms that are caused by inflammation 
(10). Even though there are many species, only a few have been studied. Among the 
many, Copaiba oil from Copaifera multijuga species and its fractions has shown to 
inhibit tumor growth in mice.  
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 Copaiba oil is a transparent liquid composed of a mixture of sesquiterpenes and 
diterpenes. Many studies indicate that the sesquiterpenes are the major component (more 
than 75%) in Copaiba oil. Because of this, the pharmacological activity can be attributed 
to the sesquiterpenes present. However, a recent study by Faiella et al. showed that some 
of the diterpenic acids may also contribute to some activity (Figure 1.8).  Hardwickiic 
acid, one of the diterpenes inhibited HSP27 which is an ATP-independent chaperone 
protein involved in tumorigenesis and thereby acknowledged to be a major therapeutic 
target in many cancer types. This finding and the similarities in their structures suggest 
that other diterpenic acids in Copaiba oil may also interact with small chaperone proteins.  
 
1.2.5 Copalic acid 
 
 Copalic acid is a diterpenic acid that is present in Copaiba oil (Figure 1.9). Its 
molecular weight is 304.47 g/mol and is a weakly acidic compound. In addition to being 
the most abundant diterpenic acid in copaiba oil, copalic acid is also found in fruits (12). 
Recent studies have demonstrated that copalic acid interferes with small chaperone 
proteins such as HSP27 and -crystallin which makes it a potential lead compound for 
the development of therapeutic agents (9). 
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Figure 1.7: The main diterpenic acids present in Copaiba oil (10).  
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Figure 1.9: The structure of copalic acid (9).  
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1.2.6 Our hypothesis 
 
 The development of resistance to treatment in prostate cancer patients 
demonstrate the need for a better therapeutic agent. Androgen receptor plays a major role 
in prostate cancer where it can stimulate the growth and survival of cancer cells in the 
presence or the absence of its ligands. Since HSP27 is involved in the stability of AR it 
can be speculated that HSP27 has an indirect role in prostate cancer. Hardwickiic acid 
obtained from copaiba oil has the ability to inhibit HSP27. Analysis of other diterpenic 
acids in copaiba oil (because of the structural similarities to harwickiic acid) revealed that 
another diterpenic acid, copalic acid, also showed inhibition of HSP27. Previously, a 
study was conducted by knocking down HSP27 with antisense oligonucleotides (ASO) or 
siRNA in order to decrease the level of AR. Since in vitro and in vivo experiments were 
successful with this siRNA named “OGX-427” a clinical trial was organized (22). Even 
though the trial seemed successful, the drawback of this strategy is related to drug 
delivery. We hypothesize that small molecules such as copalic acid may allow for 
improved drug delivery. And more potent analogs of copalic acid may be able to inhibit 
HSP27 at a higher level which would lead to decreased AR activity. 
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CHAPTER II 
 
EVALUATION OF A SMALL MOLECULE AGONIST OF EPHA2 RECEPTOR 
TYROSINE KINASE 
 
2.1 INTRODUCTION 
 
Cancer is a disease that begins when cells grow uncontrollably. The normal 
process of cell division and death is disturbed, and the orderly progression is changed. 
According to the American Cancer Society, about 1.7 million new cases of cancer are 
projected to be diagnosed in 2018 and about 600,000 deaths are expected (1). Even 
though there are no specific factors that can cause cancer, there are some that are 
speculated to pose a greater risk, such as genetics, diet, infections, or exposure to 
carcinogens (1). There are many types of cancer, including breast, prostate, bladder, 
kidney, and lung cancer to name a few. Cancer may arise in any tissue and travel and 
spread to other parts of the body in a process known as metastasis. This stage is severe 
since it is not confined to one part of the body, and therefore it is more difficult to treat at 
which point the patient’s probability of survival is decreased. There are several treatment 
options that are available such as chemotherapy, radiation therapy, hormone therapy, or 
surgery. These treatments are often accompanied by undesirable side effects. Because of 
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this, there is a need for the development of a treatment with improved efficacy, potency, 
and minimal side effects. 
Recently, it was discovered that a member of RTK family, EphA2, may prove to 
be a viable target in developing anti-cancer agents.  EphA2 belongs to the Eph receptors 
which is the largest group of RTKs. Eph receptors are involved in signal transduction and 
cell-cell communication (10). They are transmembrane proteins with an extracellular 
binding domain and a region that expands into the cytoplasm consisting of a kinase 
domain (10). Eph receptors have native ligands known as ephrins whose binding causes 
the internalization of the receptors. The binding can result in the oligomerization of 
receptor-ligand and receptor-receptor complexes which will depend on the cellular 
context of the cells (10). These interactions lead to the phosphorylation of tyrosines 
activating the kinase domain which would then regulate its downstream proteins that are 
involved in the regulation of cell survival and proliferation (10).  
EphA2 receptor is a 130 kDa glycoprotein receptor that is predominant in the 
nervous system in the embryonic developmental stage, angiogenesis, and adult epithelial 
cells (5, 13). In addition to the ligand dependent pathway, EphA2 also has a ligand 
independent pathway (10).  In the absence of its ligand, ephrin-A1, the receptor is 
activated through phosphorylation by Akt, a serine/threonine protein kinase, that induces 
cell migration. These seemingly contradictory roles of EphA2 receptor have been 
correlated with tumor progression and malignancy especially in cancers such as 
glioblastoma, breast, melanoma, and prostate carcinoma (12). In breast epithelial cells, 
EphA2 was reported to induce morphological transformation, while in prostate cancer 
and glioma cell lines elevated levels of EphA2 caused increased chemotactic cell 
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migration and invasion (10). In cancer, the overexpression of EphA2 is associated with a 
decrease in the level of ephrin-A1. And this amplifies the migratory stimulatory effects in 
the oncogenic cells. The ligand-independent pathway seems to be dominant in cancer 
cells (1). Since the ligand-dependent pathway suppresses cell migration this approach has 
potential to become a novel therapeutic strategy. 
Recently, a small molecule, doxazosin, was identified as an EphA2 agonist which 
activated the receptor in a manner similar to the native ligand, ephrin-A1. Doxazosin is 
an FDA approved drug, commonly known as Cardura®, which is being used for the 
treatment of hypertension and the improvement of urination in men suffering with benign 
prostate hyperplasia (2, 12). It produces anti-hypertensive effects by blocking 1-
adrenoreceptor and thereby inducing a decrease in the systemic vascular resistance (3). 
However, it was confirmed that in oncogenic cells activation of EphA2 and its inhibitory 
effects were not due to indirect effects of the suppression of 1-adrenoreceptor by 
doxazosin (1).  Studies showed that doxazosin exhibited effects similar to those caused 
by ligand-binding; Binding of doxazosin resulted in the internalization and degradation of 
the receptor, and also the inhibition of the Akt kinase pathways that are responsible for 
stimulation of tumor progression (1). This provides a basis for the development of more 
potent compounds using doxazosin as a lead compound. 
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2.2 RESULTS AND DISCUSSION 
 
2.2.1 Lead optimization to generate doxazosin analogs 
 
 From previous studies it was discovered that doxazosin, an 1-adrenoreceptor 
blocker, behaved in a similar manner to the native ligand of EphA2, ephrin-A1. Although 
commonly used to treat high blood pressure and urinary retention linked with benign 
prostate hyperplasia, doxazosin also activated EphA2 to induce the ligand dependent 
pathway to inhibit breast, glioma, and prostate tumor cell migration in vitro and prostate 
tumor metastasis in vivo (10). In this study, we generated 33 compounds using doxazosin 
as the lead compound using combinatorial chemistry strategy. As shown in Figure 2.1, 
the moieties A, B, and C were changed systematically, and some symmetric compounds 
were synthesized as well. The latter were generated subsequently by attaching the best C 
moiety on both sides of the piperazine ring in order to determine if A and B moieties are 
necessary. Moreover, in line with this hypothesis of symmetric compounds adapted from 
a recent study, dimeric molecules were also synthesized to gauge the activity by 
modifying the B moiety to various substituted amines. 
 In compounds 1-24, the C moiety contained various aromatic rings and alkyl 
groups (Figure 2.2). Compounds 25 and 26 were symmetric molecules with the 
piperazine ring as the core structure synthesized with a C moiety (Figure 2.3). Figure 2.4 
shows the synthesis scheme for generating the dimeric compounds, 27 and 28, with 
various linkers between the piperazine rings of the main compound. In order to explore 
whether the primary amino group is necessary for the activity, the B moiety was modified 
into different substituents. Doxazosin and compound 24 were acetylated to generate 
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compounds 29 and 30, respectively (Figure 2.5). Furthermore, the B moiety in compound 
24 was substituted with alkyl groups to synthesize compounds 31 and 32 (Figure 2.6). 
Finally, the A moiety was changed from a methoxy group to ethoxy group in compound 
24 to generate compound 33 (Figure 2.7). 
In order to evaluate the activity of these 33 analogs, MDA-MB-231 breast cancer 
cells line which overexpresses EphA2 receptor (MDA-MB-231-A2) was used. EphA2 
receptor activation was measured by calculating the ratio of phosphorylated EphA2 over 
the total EphA2 protein present after treatment with each analog. Using 50 M doxazosin 
as the positive control and 0.5% DMSO as the negative control, the cells were treated 
with 2, 10, and 50 M concentrations of the compounds. The EphA2 receptor activation 
by 50 M doxazosin was used as the cutoff point to determine the potency of the new 
compounds. Some compounds had diminished activity while several compounds showed 
an improvement: Compounds 22, and 24, which has slightly or very bulky electron 
donating substituents, respectively, showed higher activity compared to doxazosin. 
Among the dimer structures, compound 27 showed much improved potency compared to 
compound 28 (Figure 2.8). The latter consists of a shorter linkage compared to compound 
27 which suggests that the length of the linker is important for the activity.  
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Figure 2.1: Proposed modifications to the structure of doxazosin. 
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Figure 2.2: Synthesis of doxazosin analogs with substituted C moiety. 
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Figure 2.3: Synthesis of symmetric analogs using piperazine ring as core structure. 
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Figure 2.4: Synthesis of dimers. 
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Figure 2.5: Synthesis of B moiety acetylated analogs. 
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Figure 2.6: Synthesis of B moiety modified analogs. 
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Figure 2.7: Synthesis of A moiety modified analogs. 
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2.2.2 Internalization of EphA2 
 
 The overexpression of EphA2 together with a decrease in the level of its native 
ligand and binding is implicated in tumorigenesis in many cancers (4, 7, 8). Previous in 
vitro studies have shown that monoclonal antibodies or small molecule ligands can be 
used to overcome this ligand-independent pathway of EphA2 (4). And it is speculated 
that these oncogenic effects may be reversed by ligand binding (9). Unlike in the ligand-
independent pathway, when the ligand binds to EphA2 receptor, the receptor is 
internalized by endocytosis and degradation (9, 10). Since doxazosin behaved in a similar 
manner to ephrin-A1 in activating the kinase, it was important to investigate whether the 
compounds caused internalization. 
In order to investigate this phenomenon, immunofluorescence was used to 
monitor the localization of EphA2 receptor after the treatment with the compounds. We 
chose compound 27 for these studies since it had the highest activity in the initial 
screening and also because of its novel dimeric structure. The breast cancer cell line, 
MDA-MB-231, was used for this experiment and ephrin-A1-Fc was used as a positive 
control. As demonstrated in Figure 2.9, majority of EphA2 was internalized after 60 min 
of treatment with ephrin-A1-Fc. Consistent with its activity, doxazosin was also able to 
cause internalization at 50 M. Compound 27 was able to induce internalization even at a 
low concentration of 0.4 M, which indicates that it has increased potency compared to 
the lead compound.  
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Figure 2.8: Activation of EphA2 by the most potent compounds, 24 and 27. 
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2.2.3 Docking studies with compounds 24 and 27 
 
 The ligand binding domain has been identified through NMR (Nuclear Magnetic 
Resonance) and other biological assays in previous studies. Since several of the 
doxazosin analogs showed improved activity compared to doxazosin it was important to 
investigate the docking of the compounds. This would elucidate the structural 
components that are important for stronger interactions with the binding domain. In 
addition to compound 27, compound 24 was also chosen for this study since it was also 
an active compound. The docking studies were performed with doxazosin, compound 24, 
and compound 27 with the crystal structure of the EphA2 extracellular domain (The 
structure with the PDB code 3FL7 was used) (6). The 1st panel in Figure 2.10 shows the 
interaction of doxazosin with the ligand binding domain where it forms hydrogen bonds 
with GLY51, SER68, and ARG103. Moreover, the dihydrobenzo-dioxine moiety of 
doxazosin fits into a hydrophobic pocket. Comparatively, compound 24 (2nd panel) forms 
more hydrogen bonds: the methoxy group forms a hydrogen bond with GLY51 since the 
bulkiness of the aromatic group (compared to doxazosin) positions the methoxy group 
closer, the aromatic amino group forms hydrogen bonds with GLY51 and SER68, and the 
ketone of the amide bond forms a hydrogen bond with ARG103. Compound 27, 
illustrated in the 3rd panel, shows a different binding pattern compared to both doxazosin 
and compound 24. The bulkiness of compound 27 prevents it from fitting into the 
hydrophobic pocket of the binding domain and is seen to adapt into two grooves of the 
protein. The length of the linker seems to be critical for this conformation since a shorter 
linker would not be able to provide enough flexibility to bind to the groove. In addition to 
the hydrophobic interaction, compound 27 also form 4 hydrogen bonds: two hydrogen  
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Figure 2.9: Internalization of EphA2 receptor after treatment with doxazosin and 
compound 27. 
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bonds are formed by the nitrogen in the quinazoline ring with ARG103, and the other two 
hydrogen bonds are formed between the ketone and ARG103.  
 
2.2.4 Adrenoreceptor binding  
 
Doxazosin was initially used to treat hypertension and benign prostate hyperplasia due to 
its 1-adrenoreceptor antagonistic activity.  However, when it was discovered that 
doxazosin also activated EphA2, it was confirmed in previous studies that this activation 
was independent of -adrenoreceptor activity. When synthesizing the analogs, our goal 
was to enhance the potency in activating EphA2 but eliminate the -adrenoreceptor 
binding activity of doxazosin. In order to analyze this, competition experiments for 
binding -adrenoreceptor were performed with the analogs. Doxazosin was used as a 
positive control and prazosin, which is also an -adrenoreceptor antagonist, was used as 
the competitor. The results show that doxazosin displaced a higher percentage of prazosin 
and competed to bind to -adrenoreceptor more than the analogs, compounds 24 and 27  
(Figure 2.11). This is evident in the IC50 values: doxazosin showed a value of 0.74 ± 0.30 
nM and compounds 24 and 27 had IC50 values of 4.28 ± 3.10 nM and 2.50 ± 1.62 nM, 
respectively. Even though the structure activity relationship about the binding was not 
elucidated, this is an indication that the modifications to doxazosin reduced the original 
-adrenoreceptor binding affinity.  
 
 
47 
 
  
 
  
   
  
 
Figure 2.10: Docking of doxazosin, and compound 24 and 27 with EphA2 receptor’s 
ligand binding domain. 
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2.2.5 Pharmacokinetic studies with compound 27 
 
 The in vitro studies with compound 27 demonstrated that it was able to activate 
the EphA2 receptor similar to doxazosin. Compound 27 formed 4 hydrogen bonds in the 
ligand binding domain compared to the 3 formed by doxazosin and hence showed 
increased activity. The -adrenoreceptor targeting effect was also reduced in compound 
27 which further validates that its action is through the EphA2 receptor. Since in vitro 
results were promising, next we explored the pharmacokinetic profile of compound 27. 
Three-month-old female mice were divided into two groups and compound 27 was 
administered via subcutaneous (SC) or intraperitoneal (IP) injection. Blood samples and 
brain tissue from these two different sets of mice were collected at different time points. 
In order to analyze the pharmacokinetic profile of compound 27, an LC-MS/MS method 
was developed. 
First, the parameters of the mass spectrometer were optimized for the detection of 
compound 27. Prazosin, which has a similar structure to doxazosin was used as the 
internal standard (IS) (Figure 2.12). Positive ionization mode was selected for the 
detection based on the structure of compound 27 after introducing 50 ng/mL with 10 
ng/mL of the IS in acetonitrile/water (4:1, v/v) through direct infusion. The mass spectra 
of compound 27 and IS showed molecular ions at [M+2H]+ 387.3 and [M+H]+ 384.1, 
respectively. The three most abundant ions after the fragmentation of compound 27 were 
found at m/z 290.1, 247.1, and 231 (Figure 2.13 A) whereas the product ions of IS were 
m/z 247.2, 231.1, and 95.1 (Figure 2.13 B). The proposed structures of the fragmented 
ions are shown in Figure 2.14. For quantification, the multiple reaction monitoring 
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Figure 2.11: Binding of a-adrenoreceptor by doxazosin, and compounds 24 and 27. 
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 (MRM) transitions of m/z 387.3 → 290.1 was selected for compound 27, and m/z 384.1 
→ 247.1 was used for the IS. The other MRM transitions m/z 387.3 → 247.1 and 387.3 
→ 231 for compound 27 and 384.1 → 231.1 and 384.1 →95.1 for IS were also monitored 
for qualitative accuracy. For the chromatographic separation, gradient elution with a 
water/acetonitrile mobile phase with 0.1 % formic acid was used (Table I). Compound 27 
eluted at 4.22 min and the IS eluted at 4.04 min. After optimizing the detection 
parameters, the LC-MS/MS method was validated for the quantification of compound 27. 
The plasma and brain tissue samples were extracted using the liquid-liquid extraction 
(LLE) method with ethyl acetate since the protein precipitation (PPT) method generated 
substantial matrix effects. The calibration curve was obtained using blank plasma and 
brain homogenate supernatant, and 7 non-blank calibration standards whose 
concentrations were 2, 5, 10, 20, 50, 100, and 200 ng/mL. The peak area ratio of 
compound 27 to the IS (y) vs. compound 27 concentration (x) was plotted using a 
weighted (1/x) linear regression. The compound 27 calibration curves in both mouse 
plasma and brain tissue were highly linear from 2 to 200 ng/mL with the correlation 
coefficients (r) greater than 0.99 (data not shown).  
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Figure 2.12: Structure of Prazosin. 
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Figure 2.13: Product ion spectra of compound 27 (A) and prazosin (B). 
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Figure 2.14: Proposed structures of the product ions of compound 27 and prazosin. 
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Table I: HPLC gradient program used for the elution of compound 27 and ISa. 
 
 
a Mobile phase A was 2% acetonitrile with 0.1% formic acid and mobile phase B was 
100% acetonitrile with 0.1% formic acid. 
 
  
Minutes B% 
0-1 10 (isocratic) 
1-4 10-90 (linear) 
4-9 90 (isocratic) 
9-10 10 (linear) 
10-17 10 (isocratic) 
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 The selectivity and sensitivity of this LC-MS/MS method was evaluated by 
analyzing blank plasma and brain homogenate, and the Lower Limit of Quantitation 
(LLOQ) sample (1 ng/mL). The MRM chromatograms of blank plasma, brain 
homogenate, LLOQ sample spiked with IS, mouse plasma collected at 24 h after the 
administration of compound 27 and spiked with IS, mouse brain homogenate collected at 
24 h after the administration of compound 27 and spiked with IS were compared (Figure 
2.15). At 4.22 and 4.04 min no endogenous interference was observed for compound 27 
and the IS, respectively. The chromatogram of compound 27 at LLOQ level showed a 
signal-noise ratio above 10. 
 The relative matrix effect and extraction efficiency from mouse plasma were 
evaluated at concentrations of 3, 25, and 160 ng/mL. The relative matrix effect of all the 
3 concentrations are approximately 110% which indicates minimal matrix effects (Table 
II). The relative extraction efficiency for the 3 concentrations ranged from 93% to 102% 
which indicates that the extraction method is efficient to meet the requirements of 
quantification. Because of the limited availability of blank brain homogenate, the matrix 
effect was only evaluated at 3 ng/mL and was found to be in the same range as the 
plasma matrix effect.  
The precision and accuracy of the intra-assay and inter-assay were analyzed at 3 
different concentrations of 3, 25, and 160 ng/mL. As shown in Table III, the precision 
(%CV) and accuracy (%RE) for all the quality control (QC) plasma samples were within 
  
56 
 
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0
1x10
3
2x10
3
3x10
3
4x10
3
In
ten
sit
y, 
cp
s
Time (min)
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0
1x10
3
2x10
3
In
ten
sit
y, 
cp
s
(A)
 
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0.0
5.0x10
4
1.0x10
5
Time (min)
4.04
(B)
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0.0
5.0x10
3
1.0x10
4
1.5x10
4
In
ten
sit
y, 
cp
s
In
ten
sit
y, 
cp
s
4.23
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0.0
5.0x10
4
1.0x10
5
In
ten
sit
y, 
cp
s
Time (min)
4.03
(C)
3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
0.0
2.0x10
4
4.0x10
4
6.0x10
4
In
ten
sit
y, 
cp
s 4.22
 
Figure 2.15: Chromatogram of blank plasma and brain homogenate (A), compound 27 
and IS in mouse plasma (B), and brain homogenate (C).  
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Table II: Relative matrix effect and extraction efficiency of compound 27 in plasma. 
 
Compound 27 
Concentration (ng/ml) 
Relative matrix effects Relative extraction 
efficiency 
3 109.0% 92.6% 
25 111.6% 99.7% 
160 110.1% 101.8% 
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15% in both the intra- and inter-assays which indicates that the precision and accuracy of 
this method fulfills the FDA criteria for the quantitative determination of drug 
concentration in biological matrices.   
 The stability of compound 27 in mouse plasma was determined at various storage 
conditions by measuring the concentrations of the compound in QC samples after storage 
and comparing the results with the theoretical value. As shown in Table IV, there was no 
significant degradation of compound 27 in mouse plasma after storing at room 
temperature for 6 and 24 h, at 20oC for 30 days, and after 3 freeze/thaw cycles. 
Compound 27 was stable in mouse plasma at room temperature for at least 24 h with a 
recovery of >90%. The storage stability at 20oC for 30 days was 85.6% and 90.4% at low 
QC (LQC) and high QC (HQC) levels, respectively. The recovery of compound 27 after 
3 freeze/thaw cycles was 87%, and 92.7% at LQC and HQC levels, respectively. 
 This validated LC-MS/MS method was used to quantify the amount of compound 
27 in plasma and brain tissue of mice after dosing at different times. Two sets of plasma 
and brain tissue samples were collected after IP or SC administration of a single dose of 
10 mg/kg compound 27 in phosphate buffered saline (PBS) with 10% Cremophor. The 
concentration of compound 27 in plasma and brain tissue at different time points was 
collected for both administration routes. With IP injection, a maximum concentration of 
54 ng/mL was reached in plasma at 15 min, whereas with SC injection a maximum 
concentration of about 150 ng/mL between 30 min and 4 h of administration (Figure 
2.16). The diverse pharmacokinetic profiles after the two different types of administration 
suggest that compound 27 may undergo phase I metabolism at different levels. IP 
injection is very likely to result in the metabolism of compound 27 in the mouse liver  
59 
 
 
 
 
 
 
 
 
 
Table III: Intra-assay and Inter-assay for the quantification of compound 27 in mouse 
plasma. 
 
                    Intra-assay (n=5) Inter-assay (n=5) 
Spiked 
conc. 
(ng/ml) 
Determined 
conc. 
(ng/ml)±SD 
Precision 
(% CV) 
Accuracy 
(% RE) 
Determined 
conc. 
(ng/ml)±SD 
Precision 
(% CV) 
Accuracy 
(% RE) 
3 2.64 ± 0.03 1.1 -12 2.60 ± 0.1 3.8 -13.3 
25 22.4 ± 1.89 8.4 -10.4 22.6 ± 0.15 0.66 -9.6 
160 149 ± 3.74 2.5 -6.9 150.6 ± 5.0 3.3 -5.9 
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Table IV: Analysis of the stability of compound 27 in mouse plasma. 
 
 
 
  
Storage 
Conditions (n= 3) 
Spiked conc. 
(ng/ml) 
Determined conc. 
(ng/ml)±SD 
Recovery (%) 
At room 
temperature for 4 hr 
3 
160 
2.88  ± 0.16 
151 ± 5.6 
96 
94.3 
At room 
temperature for 24 
hr 
3 
160 
2.76 ± 0.01 
151.3  ±  7.8 
92.0 
94.5 
Three freeze-thaw 
cycles 
3 
160 
2.62 ± 0.06 
148.3  ±  4.7 
87.0 
92.7 
Long-term stability 
(at -20°C for 30 
days) 
3 
160 
2.57± 0.10 
144.7  ±  8.5 
85.6 
90.4 
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leading to a lower maximum concentration compared to that which is administered via 
SC injection. In the brain, the maximum concentration of compound 27 was 5 pg/mL at 5 
h with IP injection, and 26 ng/ml at 3 h with SC injection. These results indicate that a 
portion of compound 27 that is in circulation may pass through the blood brain barrier 
and accumulate in brain tissue.  
 The results from the pharmacokinetic studies reveal that compound 27 may be 
subjected to first pass metabolism. Therefore, further investigation of compound 27’s 
metabolites may provide valuable information for the optimization of its structure to 
improve its pharmacokinetic behavior. Compound 27 was also able to pass the blood 
brain barrier which suggests that it can ultimately be used for the treatment of 
glioblastoma. Further studies would include evaluation of EphA2 agonist activity and 
therapeutic efficacy of compound 27 in vivo. Based on those results the structure of 
compound 27 can be optimized to increase efficacy and potency. Thus far, the results 
have been promising in generating a novel anti-cancer agent that functions as an EphA2 
agonist to inhibit tumor progression. 
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Figure 2.16: Pharmacokinetic profile of compound 27 in mouse plasma and brain after IP 
(A) and SC (B) administration. 
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2.3 MATERIALS AND METHODS 
 
2.3.1 Chemistry 
 
Chemicals were commercially available and used as received without further 
purification unless otherwise noted. Moisture sensitive reactions were carried out under a 
dry argon atmosphere in flame-dried glassware. Solvents were distilled before use under 
argon. Thin-layer chromatography (TLC) was performed on pre-coated silica gel F254 
plates (Whatman). Column chromatography was performed using silica gel 60Å (Merck, 
230-400 Mesh), and hexane/ethyl acetate was used as the elution solvent. Mass spectra 
were obtained on the electrospray mass spectrometer at Cleveland State University MS 
facility Center. The molecular weight of the compounds was examined with LC-MS. All 
the NMR spectra were recorded on a Bruker 400 MHz in either DMSO-d6 or CDCl3. 
Chemical shifts () for 1H NMR spectra are reported in parts per million to residual 
solvent protons.  
HPLC grade acetonitrile and ACS grade ethyl acetate were purchased from BDH 
chemicals (Carle Place, NY) and LC-MS grade formic acid was purchased from Fisher 
Scientific (Waltham, MA). Deionized water was purified using a Barnstead NANOpure® 
water purification system from Thermo Scientific (Waltham, MA). Six different lots of 
Non Swiss Albino Mouse plasma were obtained from Innovative Research (Novi, MI).  
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2.3.2 Synthesis of doxazosin analogs 
 
Compounds 1-24, 27 and 28 were prepared according to the following procedure.  
Dimethoxyquinazolin and piperazine were dissolved in n-butanol (n-BuOH) with 1 
to 5 mole ratio, and the mixture was heated to 100°C for 24 h and cooled down to room 
temperature. The precipitated while solid was collected via filtration and washed with n-
BuOH. After it was dried, the solid was mixed with different substituted acetyl chlorides 
and potassium carbonate (K2CO3) in dimethylformamide (DMF). It was stirred until the 
reaction was completed. The reaction was quenched with sodium carbonate (Na2CO3) 
aqueous solution and stirred overnight, and the precipitated product was collected via 
filtration and washed with water and dried to give the corresponding compounds.    
Compound 1: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (naphthalen-
2-yl) methanone 
White solid, melting point 2226-229°C, 72% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 8.016 (4H, m), 7.580 (3H, m), 7.440 (1H, s), 7.167 (2H, br), 6.745 (1H, s), 
3.795 (12H, m), 3.490 (2H, br). 13C-NMR (100MHz, DMSO-d6) δ 169.642, 161.632, 
158.757, 154.699, 149.117, 145.535, 133.709, 132.754, 130.970, 129.745, 128.525, 
127.826, 125.353, 105.645, 104.111, 103.460, 67.487, 56.294, 66.889, 25.592. DUIS-MS 
calculated for C25H25N5O4 [M + H]
+: 444.1, found : 443.5 
Compound 2: [1,1'-biphenyl]-3-yl(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-
1-yl)methanone 
White solid, melting point 179-182°C, 73% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.735 (4H, m), 7.498 (6H, m), 7.152 (2H, br), 6.740 (1H, s), 3.794 (12H, 
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m), 3.464 (2H, m). 13C-NMR (100MHz, DMSO-d6) δ 169.475, 161.620, 158.802, 
154.687, 149.184, 145.519, 140.765, 139.825, 137.207, 129.509,128.279, 127.297, 
126.522, 125.633, 105.669, 104.085, 103.455, 56.287, 66.879. DUIS-MS calculated for 
C27H27N5O3 [M + H]
+: 470.1, found : 469.2 
Compound 3: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (benzo [d] [1,3] 
dioxol-5-yl) methanone 
White solid, melting point 267-269°C,  71% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.431 (1H, s), 7.145 (2H, br), 6.981 (3H, m), 6.736 (1H, s), 6.094 (2H, s), 
3.791 (10H, m), 3.541 (4H, br). 13C-NMR (100MHz, DMSO-d6) δ 169.133, 161.610, 
158.769, 154.682, 149.187, 148.700, 147.605, 145.499, 130.049, 121.990, 108.458, 
105.666, 104.094, 103.440, 101.901, 56.503, 56.283, 55.878, 44.074, 19.023. DUIS-MS 
calculated for C22H23N5O5 [M + H]
+: 438.1, found : 437.5 
Compound 4: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-(4-
methoxyphenyl) ethanone 
White solid, melting point 240-243°C, 65% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.422 (1H, s), 7.168 (4H, m), 6.881 (2H, d, J= 8.8 Hz), 6.734 (1H, s), 3.831 
(3H, s), 3.788 (3H, s), 3.729 (3H, s), 3.671 (4H, m), 3.601 (2H, br), 3.532 (4H, br). 13C-
NMR (100MHz, DMSO-d6) δ 169.795, 161.584, 158.522, 154.669, 149.169, 145.485, 
130.419, 128.163, 114.233, 105.668, 104.061, 103.412, 56.276, 55.662, 45.928, 44.254, 
43.886, 41.754. DUIS-MS calculated for C23H27N5O4 [M + H]
+: 438.1, found : 437.5 
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Compound 5: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-(3-
methoxyphenyl) ethanone 
White solid, melting point 198-201°C, 60% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.423 (1H, s), 7.231 (1H, m), 7.143 (1H, br), 6.817 (3H, m), 6.737 (1H, s), 
3.830 (3H, s), 3.788 (3H, s), 3.738 (5H, m), 3.598 (9H, m). 13C-NMR (100MHz, DMSO-
d6) δ 169.382, 161.590, 159.707, 158.745, 154.676, 149.159, 145.495, 137.832, 129.834, 
121.631, 115.114, 112.281, 105.662, 104.060, 103.416, 67.488, 56.275, 55. 643, 45.977, 
44.237, 43.878, 41.783. DUIS-MS calculated for C23H27N5O4 [M + H]
+: 438.1, found : 
437.5 
Compound 6: 1- (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-phenylethanone 
White solid, melting point 221-223°C, 96% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.420 (1H, s), 7.272 (5H, m), 7.140 (2H, br), 6.733 (1H, s), 3.829 (3H, s), 
3.786 (3H, s), 3.775 (2H, s), 3.607 (8H, m). 13C-NMR (100MHz, DMSO-d6) δ 169.500, 
161.590, 158.759, 154.674, 149.173, 145.492, 136.385, 129.469, 128.807, 126.828, 
105.672, 104.064, 103.419, 56.279, 55.877, 45.955, 44.239, 43.883, 41.778. DUIS-MS 
calculated for C22H25N5O3 [M + H]
+: 408.1, found : 407.2 
Compound 7: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-(naphthalen-2-yl) 
ethenone 
White solid, melting point 236-238°C, 70% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.862 (3H, m), 7.774 (1H, s), 7.436 (4H, m), 7.133 (2H, br), 6.725 (1H, s), 
3.957 (2H, s), 3.823 (3H, s), 3.782 (3H, s), 3.610 (8H, m). 13C-NMR (100MHz, CDCl3-
d6) δ 169.688, 160.521, 158.510, 155.158, 149.759, 145.970, 133.577, 132.459, 128.540, 
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127.446, 126.517, 125.780, 105.814, 102.901, 101.134, 56.160, 46.256, 43.913, 41.707. 
DUIS-MS calculated for C26H27N5O3 [M + H]
+: 458.1, found : 457.5 
Compound 8: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-phenylpropan-1-
one 
White solid, melting point 207-209°C, 82% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.400 (1H, s), 7.306 (5H, m), 7.112 (2H, br), 6.704 (1H, s), 4.155 (1H, q, J= 
6.8 Hz), 3.816 (3H, s), 3.775 (3H, s), 3.680-3.399 (6H, m), 3.007 (1H, m), 1.316 (3H, d, 
J= 6.8 Hz). 13C-NMR (100MHz, CDCl3-d6) δ 172.254, 160.514, 158.541, 155.142, 
149.783, 145.917, 142.085, 128.993, 127.214, 126.849, 105.782, 102.866, 101.177, 
56.091, 45.570, 43.777, 42.118, 20.719. DUIS-MS calculated for C22H23N5O5 [M + H]
+: 
422.1, found : 421.5 
Compound 9: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (pyridin-2-yl) 
methanone  
White solid, melting point 250-252°C, 42% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 8.625 (1H, d, J= 4.4 Hz), 7.952 (1H, t, J= 8 Hz), 7.615 (1H, d, J= 8 Hz), 
7.507 (1H, m), 7.432 (1H, s), 7.156 (2H, br), 6.738 (1H, s), 3.831-3.726 (12H, m), 3.469 
(2H, m). 13C-NMR (100MHz, DMSO-d6) δ 167.378, 161.623, 158.737, 154.599, 
149.175, 148.901, 145.529, 137.864, 125.097, 123.712, 105.685, 104.109, 103.456, 
56.299, 55.886, 47.042, 44.409, 43.866, 42.193. DUIS-MS calculated for C20H22N6O3 [M 
+ H]+: 395.1, found : 394.4 
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Compound 10: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (pyridin-4-yl) 
methanone 
White solid, melting point 235-237°C, 32% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 8.697 (2H, d, J= 4.8 Hz), 7.444 (3H, m), 7.163 (2H, br), 6.735 (1H, s), 
3.830-3.710 (14H, m) (Note: it seems that two protons are missing but they may overlap 
with the peak from water). 13C-NMR (100MHz, DMSO-d6) δ 167.422, 161.632, 158.709, 
154.711, 150.553, 149.161, 145.559, 143.952, 121.794, 105.669, 104.104, 103.463, 
56.301, 55.896, 47.319, 44.215, 43.737, 41.990. DUIS-MS calculated for C20H22N6O3 [M 
+ H]+: 395.1, found : 394.4 
Compound 11: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (4-ethylphenyl) 
methanone 
White solid, melting point 240-242°C, 84% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.433 (1H, s), 7.370 (2H, d, J= 8 Hz), 7.302 (2H, d, J= 8 Hz), 7.154 (2H, 
br), 6.735 (1H, s), 3.831-3.445 (14H, m), 2.660 (2H, q, J= 7.6 Hz), 1.214 (3H, t, J= 7.6 
Hz). 13C-NMR (100MHz, DMSO-d6) δ 169.768, 161.614, 158.774, 154.687, 149.181, 
145.696, 133.742, 128.206, 127.749, 105.667, 104.088, 103.453, 56.284, 55.877, 28.458, 
15.801. DUIS-MS calculated for C23H27N5O3 [M + H]
+: 422.1, found : 421.5 
Compound 12: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (4-iodophenyl) 
methanone 
White solid, melting point 254-258°C, 85% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.843 (2H, d, J= 8 Hz), 7.423 (1H, s), 7.252 (2H, d, J= 8 Hz), 7.144 (2H, 
br), 6.735 (1H, s), 3.841-3.716 (14H, m). 13C-NMR (100MHz, DMSO-d6) δ 168.865, 
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161.618, 158.734, 154.704, 149.161, 145.533, 137.730, 135.857, 129.657, 105.670, 
104.110, 103.454, 96.865, 56.301, 55.893. DUIS-MS calculated for C21H22IN5O3 [M + 
H]+: 520.0, found : 519.3 
Compound 13: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (4-chloro-3-
nitrophenyl) methanone 
White solid, melting point 268-272°C, 91% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 8.179 (1H, s), 7.883 (1H, d, J= 8 Hz), 7.792 (1H, d, J= 8 Hz), 7.434 (1H, 
s), 7.159 (2H, br), 6.740 (1H, s), 3.833-3.401 (14H, m). 13C-NMR (100MHz, DMSO-d6) 
δ 166.451, 161.632, 158.722, 154.699, 149.143, 148.029, 145.547, 136.683, 132.589, 
126.400, 124.905, 105.664, 104.089, 103.456, 56.293, 55.892. DUIS-MS calculated for 
C21H21ClN6O5 [M + H]
+: 473.0, found : 472.9 
Compound 14: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)ethanone 
White solid, melting point 244-247°C, 88% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.426 (1H, s), 7.143 (2H, br), 6.745 (1H, s), 3.836-3.684 (10H, m), 3.490 
(4H, m), 2.050 (3H, s). 13C-NMR (100MHz, DMSO-d6) δ 168.845, 161.606, 158.768, 
154.682, 149.209, 145.469, 105.675, 104.106, 103.410, 56.289, 55.885, 46.158, 44.261, 
43.872, 41.361, 21.803. DUIS-MS calculated for C16H21N5O3 [M + H]
+: 332.1, found : 
331.4 
Compound 15: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)propan-
1-one 
White solid, melting point 269-272°C, 63% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.428 (1H, s), 7.141 (2H, br), 6.746 (1H, s), 3.837-3.686 (10H, m), 3.507 
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(4H, m), 2.366 (2H, q, J= 7.2 Hz), 1.017 (3H, t, J= 7.2 Hz). 13C-NMR (100MHz, 
DMSO-d6) δ 171.950, 161.602, 158.795, 154.682, 149.227, 145.466, 105.680, 104.110, 
103.413, 56.289, 55.879, 45.251, 44.304, 43.930, 41.538, 26.125, 9.897. DUIS-MS 
calculated for C17H23N5O3 [M + H]
+: 346.1, found : 345.4 
Compound 16: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)butan-1-
one 
White solid, melting point 259-262°C, 72% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.426 (1H, s), 7.142 (2H, br), 6.743 (1H, s), 3.836 (3H, s), 3.791 (3H, s), 
3.735 (2H, m), 3.683 (2H, m), 3.507 (4H, m), 2.337 (2H, t, J=7.2 Hz), 1.555 (2H, m), 
0.914 (3H, t, J= 7.6 Hz). 13C-NMR (100MHz, DMSO-d6) δ 171.13, 161.60, 158.78, 
154.68, 149.23, 145.47, 105.68, 104.11, 103.41,67.49, 56.29, 55.86, 45.41, 44.37, 43.96, 
41.49, 34.76, 25.59, 18.69, 14.31. DUIS-MS calculated for C18H25N5O3 [M + H]
+: 360.1, 
found : 359.4 
Compound 17: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) (cyclohexyl) 
methanone 
White solid, melting point 220-222°C, 89% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.429 (1H, s), 7.138 (2H, br), 6.740 (1H, s), 3.837 (3H, s), 3.792 (3H, s), 
3.703 (4H, m), 3.520 (4H, m), 2.627 (1H, m), 1.701 (5H, m), 1.336 (4H, m), 1.174 (1H, 
m). 13C-NMR (100MHz, DMSO-d6) δ 174.107, 161.596, 158.774, 154.691, 149.220, 
145.480, 105.684, 104.138, 103.432, 56.299, 55.879, 45.298, 44.640, 43.992, 41.567, 
29.631, 26.081, 25.656, 19.020. DUIS-MS calculated for C21H29N5O3 [M + H]
+: 400.2, 
found : 399.5 
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Compound 18: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-
yl)methanone 
White solid, melting point 230-233°C, 66% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.869 (1H, d, J= 0.8 Hz), 7.438 (1H, s), 7.162 (2H, br), 7.037 (1H, d, J= 3.2 
Hz), 6.752 (1H, s), 6.652 (1H, dd, J= 0.8, 3.2 Hz), 3.795 (14H, m). 13C-NMR (100MHz, 
DMSO-d6) δ 161.633, 158.862, 154.712, 149.213, 147.474, 145.521, 145.205, 116.020, 
111.775, 105.700, 104.137, 103.463, 67.487, 56.302, 55.886, 44.153, 25.591. DUIS-MS 
calculated for C19H21N5O4 [M + H]
+: 384.1, found : 383.4 
Compound 19: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(thiophen-
2-yl)methanone 
White solid, melting point 222-224°C, 56% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.784 (1H, d, J= 4.8 Hz), 7.475 (1H, d, J= 3.2 Hz), 7.438 (1H, s), 7.161 
(3H, m), 6.750 (1H, s), 3.811(10H, m), 3.761 (4H, br). 13C-NMR (100MHz, DMSO-d6) δ 
162.930, 161.637, 158, 732, 154.715, 149.215, 145.523, 137.835, 130.013, 129.650, 
127.626, 105.698, 104.143, 103.465, 56.308, 55.892, 44.090. DUIS-MS calculated for 
C19H21N5O3S [M + H]
+: 400.1, found : 399.5 
Compound 20: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(isoxazol-
5-yl)methanone 
White solid, melting point 249-251°C, 43% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 8.782 (1H, s), 7.442 (1H, s), 7.198 (2H, br), 6.984 (1H, s), 6.758 (1H, s), 
3.839-3.611 (14H, m). 13C-NMR (100MHz, DMSO-d6) δ 161.661, 157.432, 151.435, 
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145.615, 106.739, 104.129, 103.462, 56.310, 55.916. DUIS-MS calculated for 
C18H20N6O4 [M + H]
+: 385.1, found : 384.4 
Compound 21: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(4-methoxyphenyl) 
methanone  
White solid, melting point 229-232°C, 85% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.420 (3H, m), 7.148 (2H, br), 7.007 (2H, d, J= 8.4 Hz), 6.738 (1H, s), 
3.813 (13H, m), 3.557 (4H, m). 13C-NMR (100MHz, DMSO-d6) δ 169.598, 161.623, 
160.689, 158.790, 154.705, 149.211, 145.517, 129.628, 128.371, 114.131, 105.691, 
104.134, 103.458, 56.302, 55.803, 44.140. DUIS-MS calculated for C22H25N5O4 [M + 
H]+: 424.1, found : 423.5 
Compound 22: (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(4-bromophenyl) 
methanone 
White solid, melting point 128-130°C, 83% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.665 (2H, d, J= 8.4 Hz), 7.440 (1H, s), 7.407 (2H, d, J= 8.4 Hz), 7.164 
(2H, br), 6.744 (1H, s), 3.832 (3H, s), 3.793 (3H, s), 3.725 (6H, m), 3.388 (2H, br). 13C-
NMR (100MHz, DMSO-d6) δ 168.663, 161.624, 158.747, 154.710, 149.178, 145.538, 
136.589, 131.933, 129.770, 123.409, 105.679, 104.115, 103.4584, 56.303, 55.895. DUIS-
MS calculated for C21H22N5O3Br [M + H]
+: 474.0, found : 472.5 
Compound 23: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)hexan-1-
one 
White solid, melting point 170-172°C, 73% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.427 (1H, s), 7.146 (2H, br), 6.743 (1H, s), 3.834 (3H, s), 3.790 (3H, s), 
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3.731 (2H, m), 3.679 (2H, m), 3.500 (4H, m), 2.335 (2H, t, J= 7.2 Hz), 1.516 (2H, m), 
1.287 (4H, m), 0.872 (3H, t, J= 6.4 Hz). 13C-NMR (100MHz, DMSO-d6) δ 171.287, 
161.603, 158.789, 154.690, 149.226, 145.478, 105.679, 104.123, 103.424, 56.294, 
55.878, 45.433, 44.380, 43.959, 41.508, 32.789, 31.497, 24.984, 22.452, 14.356. DUIS-
MS calculated for C20H29N5O3 [M + H]
+: 388.1, found : 387.5 
Compound 24: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)-2-(4-
(benzyloxy)phenyl) ethanone  
White solid, melting point 230-234°C, 89% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.381 (6H, m), 7.169 (4H, m), 6.958 (2H, d, J= 8.4 Hz), 6.740 (1H, s), 
5.071 (2H, s), 3.830 (3H, s), 3.789 (3H, s), 3.693-3.535 (10H, m). 13C-NMR (100MHz, 
DMSO-d6) δ 169.755, 161.602, 158.781, 157.409, 154.701, 149.206, 145.510, 137.636, 
130.455, 128.410, 115.151, 105.703, 104.125, 103.441, 69.643, 67.493, 56.302, 55.879, 
45.937, 44.274, 43.903, 41.764, 25.596. DUIS-MS calculated for C29H31N5O4 [M + H]
+: 
514.2, found : 513.6 
Compound 27: 1,12-bis(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) 
dodecane-1,12-dione  
White solid, melting point 218-225°C, 68% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.425 (2H, s), 7.145 (4H, br), 6.740 (2H, s), 3.831 (6H, s), 3.787 (6H, s), 
3.700 (8H, m), 3.495 (8H, br), 2.331 (4H, t, J= 7.2 Hz), 1.504 (4H, br), 1.267 (12H, br). 
13C-NMR (100MHz, DMSO-d6) δ 171.277, 161.596, 158.786, 154.682, 149.221, 
145.467, 105.680, 104.119, 103.417, 56.293, 55.880, 45.427, 44.380, 43.958, 41.504, 
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32.834, 29. 358, 25.306. DUIS-MS calculated for C40H56N10O6 [M + H]
+: 774.0, found : 
772.9 
Compound 28: 1,6-bis(4-(4-amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl) 
hexane-1,6-dione 
White solid, melting point 279-280°C, 77% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.424 (2H, s), 7.138 (4H, br), 6.743 (2H, s), 2.846-2.507 (28H, m), 2.393 
(4H, br), 1.567 (4H, br). 13C-NMR (100MHz, DMSO-d6) δ 171.217, 161.602, 158.789, 
154.683, 149.218, 145.471, 105.679, 104.105, 103.413, 56.293, 55.882, 45.433, 44.386, 
43.962, 41.521, 32.759, 25.050. DUIS-MS calculated for C34H44N10O6 [M + H]
+: 689.1, 
found : 688.8 
Compounds 25 and 26 were prepared according to the following procedure.  
The substituted acetyl chloride and piperazine were dissolved in DMF and K2CO3 
with 2 to 1 mole ratio, and the mixture was stirred at room temperature until the reaction 
was completed. The reaction was quenched with Na2CO3 aqueous solution and stirred 
overnight, and the precipitated product was collected via filtration and washed with water 
and dried to give the corresponding compounds.    
Compound 25: piperazine-1,4-diylbis((4-methoxyphenyl)methanone) 
White solid, melting point 215°C decomposed, 86% yield for the last step;  1H-NMR 
(400MHz, DMSO-d6) δ 7.403 (4H, d, J= 8.4 Hz), 6.994 (4H, d, J= 8.4 Hz), 3.799 (6H, 
s), 3.542 (8H, br). 13C-NMR (100MHz, DMSO-d6) δ 169.643, 160.793, 129.640, 
127.996, 114.152, 55.746. DUIS-MS calculated for C20H22N2O4 [M + H]
+: 355.1, found : 
354.4 
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Compound 26: piperazine-1,4-diylbis((4-(methylthio)phenyl)methanone)  
White solid, melting point 220°C decomposed, 91% yield for the last step;  1H-NMR 
(400MHz, DMSO-d6) δ 7.378 (4H, d, J= 8.4 Hz), 7.315 (4H, d, J= 8.4 Hz), 3.355 (6H, 
s), 3.533 (8H, br). 13C-NMR (100MHz, DMSO-d6) δ 169.394, 141.119, 132.045, 
128.339, 125.694, 14.715. DUIS-MS calculated for C20H22N2O2S2 [M + H]
+: 387.1, 
found : 386.5 
Compounds 29 and 30 were prepared according to the following procedure.  
Doxazosin or compound 24 were dissolved in DMF and K2CO3, and acetyl chloride 
was added to the two reactions, respectively, with 1 to 5 mole ratio to the two 
compounds. The mixture was stirred until the reaction was completed. The reaction was 
quenched with Na2CO3 aqueous solution and stirred overnight, and the precipitated 
product was collected via filtration and washed with water and dried to give the 
corresponding compounds.    
Compound 29: N-(2-(4-(2,3-dihydrobenzo[b][1,4]dioxine-2-carbonyl)piperazin-1-yl)-
6,7-dimethoxyquinazolin-4-yl)acetamide  
White solid, melting point 269-271°C, 36% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 10.464 (1H, s), 7.477 (1H, s), 6.874 (5H, m), 5.296 (1H, dd, J= 2.4, 6.4Hz), 
4.427 (1H, dd, J= 2.4, 11.6 Hz), 4.220 (1H, dd, J=6.8, 12 Hz), 3.899 (3H, s), 3.846 (3H, 
s), 3.713 (8H, m), 2.411 (3H, s). 13C-NMR (100MHz, DMSO-d6) δ 171.532, 165.464, 
157.725, 156.160, 151.018, 146.535, 143.432, 121.912, 117.443, 105.629, 103.741, 
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69.985, 65.205, 56.267, 45.373, 44.592, 43.964, 41.858, 25.802. DUIS-MS calculated for 
C25H27N5O6 [M + H]
+: 494.1, found : 493.5 
Compound 30: N-(2-(4-(2-(4-(benzyloxy) phenyl) acetyl) piperazin-1-yl) -6,7-
dimethoxyquinazolin-4-yl) acetamide 
White solid, melting point 205-209°C, 29% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 10.436 (1H, s), 7.382 (6H, m), 7.181 (2H, d, J= 8.4 Hz), 6.958 (2H, d, J= 
8.4 Hz), 6.897 (1H, s), 5.076 (2H, s), 3.889 (3H, s), 3.838 (3H, s), 3.704 (6H, m), 3.583 
(4H, br), 2.394 (3H, s). 13C-NMR (100MHz, CDCl3-d6) δ 170.048, 157.680, 156.151, 
154.624, 151.293, 147.091, 136.950, 129.637, 128.582, 127.556, 115.237, 105.657, 
100.764, 70.084, 56.270, 45.968, 44.102, 41.715, 40.284, 25.679. DUIS-MS calculated 
for C31H33N5O5 [M + H]
+: 556.2, found : 555.6 
Compounds 31 and 32 were prepared according to the following procedure.  
The dichloro-dimethoxyquinazolin and piperidine or pyrrolidine were dissolved in n-
BuOH with 2 to 1 mole ratio, and the mixture was heated to 70°C for 24 h, and then 
cooled down to room temperature. The precipitated while solid was collected via 
filtration and washed with n-BuOH to get the corresponding intermediates. After it was 
dried, the intermediates and piperazine were dissolved in n-BuOH with 1 to 5 mole ratio, 
respectively. The two reactions were heated to 100°C for 24 h, then it was cooled down 
to room temperature. The precipitated while solid was collected via filtration and washed 
with n-BuOH to get two new intermediates, 6,7-dimethoxy-2-(piperazin-1-yl)-4- 
(piperidin-1-yl) quinazoline, 6,7-dimethoxy-2-(piperazin-1-yl)-4-(pyrrolidin-1-yl) 
quinazoline. Last, the two intermediates were mixed with 2-(4-(benzyloxy) phenyl) acetyl 
77 
 
chloride (1:1 mole ratio) and K2CO3 in DMF, respectively. The reactions were stirred 
until completed and were quenched with Na2CO3 aqueous solution and stirred overnight. 
The precipitated products were collected via filtration and washed with water and dried to 
give the corresponding compounds 31, 32.    
Compound 31: 2-(4-(benzyloxy) phenyl)-1-(4-(6,7-dimethoxy-4-(piperidin-1-yl) 
quinazolin-2-yl) piperazin-1-yl) ethanone  
White solid, melting point 160°C decomposed, 56% yield for the last step;  1H-NMR 
(400MHz, DMSO-d6) δ 7.383 (5H, m), 7.182 (2H, d, J= 8.8 Hz), 6.958 (2H, d, J= 7.2 
Hz), 6.848 (1H, s), 5.077 (2H, s), 3.861 (3H, s), 3.813 (3H, s), 3.561 (15H, m), 1.687 
(6H, br). 13C-NMR (100MHz, DMSO-d6) δ 169.778, 165.057, 157.608, 154.765, 
151.037, 145.215, 137.534, 130.440, 128.408, 115.157, 106.105, 105.426, 104.824, 
69.631, 56.021, 55.906, 50.828, 45.820, 44.325, 43.913, 41.647, 25.832, 24.832. DUIS-
MS calculated for C34H39N5O4 [M + H]
+: 582.2, found : 581.7 
Compound 32: 2-(4-(benzyloxy) phenyl)-1-(4-(6,7-dimethoxy-4-(pyrrolidin-1-yl) 
quinazolin-2-yl) piperazin-1-yl) ethanone  
White solid, melting point 137°C decomposed, 60% yield for the last step;  1H-NMR 
(400MHz, DMSO-d6) δ 7.382 (6H, m), 7.179 (2H, d, J= 8.4 Hz), 6.958 (2H, d, J= 8.4 
Hz), 6.793 (1H, s), 5.075 (2H, s), 3.815 (10H, m), 3.623 (10H, m), 1.939 (4H, m). 13C-
NMR (100MHz, DMSO-d6) δ 169.772, 159.752, 157.638, 154.027, 150.966, 144.298, 
137.636, 130.425, 128.517, 115.166, 106.435, 105.506, 69.638, 56.086, 55.829, 50.454, 
25.716. DUIS-MS calculated for C33H37N5O4 [M + H]
+: 568.2, found : 567.7 
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Compound 33 was prepared according to the following procedure.  
Boron tribromide (1:1.2 mole ratio) was added to a solution of 4-amino-2-chloro-6,7-
dimethoxyquinazoline in dichloromethane (CH2Cl2) that was cooled to -70 °C under 
argon (11). The mixture was allowed to warm to room temperature over a period of 4 h 
and was then cooled to -70 °C; methanol was added to quench the reaction, and the 
solution was concentrated. The solid residue was washed with ethyl acetate to obtain the 
intermediate 4-amino-2-chloro-6,7-dihydroxyquinazoline. A mixture of the intermediate, 
ethyl iodine and K2CO3 in DMF was stirred overnight and purified by silica gel 
chromatography to afford 4-amino-2-chloro-6,7-diethoxyquinazoline. The 
diethoxyquinazoline and piperazine were dissolved in n-BuOH with 1 to 5 mole ratio, 
and the mixture was heated to 100°C for 24 h, and then cooled down to room 
temperature. The precipitated while solid was collected via filtration and washed with n-
BuOH. After it was dried, the solid was mixed with 2-(4-(benzyloxy) phenyl) acetyl 
chloride (1:1 mole ratio) and K2CO3 in DMF. It was stirred until the reaction was 
completed. The reaction was quenched with Na2CO3 aqueous solution and stirred 
overnight, and the precipitated product was collected via filtration and washed with water 
and dried to give compound 33.    
Compound 33: 1-(4-(4-amino-6,7-diethoxyquinazolin-2-yl) piperazin-1-yl)-2-(4-
(benzyloxy) phenyl) ethanone 
White solid, melting point 248-254°C, 69% yield for the last step; 1H-NMR (400MHz, 
DMSO-d6) δ 7.383 (6H, m), 7.177 (2H, d, J= 8.4 Hz), 7.112 (2H, br), 6.958 (2H, d, J= 
8.4 Hz), 6.714 (1H, s), 5.075 (2H, s), 4.066 (4H, m), 3.590 (6H, m), 1.369 (6H, m). 13C-
NMR (100MHz, CDCl3-d6) δ 170.017, 136.987, 129.646, 128.580, 127.739, 115.192, 
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103.529, 70.075, 65.149, 46.164, 41.904, 40.295, 29.705, 14.666. DUIS-MS calculated 
for C31H31N5O4 [M + H]
+: 542.2, found : 541.6 
 
2.3.3 Cell Culture and antibodies. 
 
MDA-MB-231 cells were obtained from ATCC (Rockville, MD). The 
overexpression EphA2 protein in the cells was generated according to the procedure 
reported in a previous study (10). The cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mg/ml L-
Glutamine, 100 U/mL penicillin-streptomycin, and 0.1 mg/ml streptomycin.  EphA2 
overexpressed cells were grown in the presence of 1 µg/ml puromycin.  Cell cultures 
were grown at 37 ºC, in a humidified atmosphere of 5% CO2 in a Thermo CO2 incubator 
(Grand Island, NY).  
Antibodies used included rabbit polyclonal antibodies against pEphA/B (synthesized 
as described previously) and EphA2 (Santa Cruz, Santa Cruz, CA), as well as mouse 
monoclonal antibody to EphA2 (clone D7, Millipore, Billerica, MA) (8).  Secondary 
antibodies used were goat anti-rabbit conjugated to horseradish peroxidase (HRP) (Santa 
Cruz) and donkey anti-mouse conjugated to Alexa Fluor 488 (Thermo Fisher, Grand 
Island, NY).  
 
2.3.4 Activation of EphA2 
 
MDA-MB-231 EphA2-overexpressing cells were plated in 12-well dishes at a density 
of 100,000 cells/well and grown for 24 h prior to stimulation with appropriate compounds 
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and ephrins for 30 min and 10 min, respectively. Compounds were prepared in DMSO at 
200 times the final concentrations and 0.5% dimethyl sulfoxide (DMSO) was used as 
vehicle control. Following treatment, cells were washed and lysed in modified RIPA 
Buffer (20 mM Tris-HCl pH 7.4, 20 mM NaF, 150 mM NaCl, 10% glycerol, 0.1% SDS, 
0.5% DCA, 2 mM EDTA, 1% Triton X-100, 2 mM Na3VO4, and protease inhibitors, 
including 1 mM phenylmethylsulphonyl fluoride, and 2 µg/ml each of aprotinin and 
leupeptin) for 20 min, followed by immunoprecipitation.  For immunoprecipitation, lysates 
were combined with 10 µg of ephrin-A1-Fc and 10-15 µl of Gamma-Bind Protein G beads 
(GE Healthcare Bioscience, Pittsburgh, PA) and rotated for 3 h at 4 ºC.  10 µg of human 
unconjugated Fc was used as a negative control.  Beads were pelleted at 9,000 rpm for 2 
min at 4 ºC and washed twice with 1 ml of IP Wash Buffer (20 mM Tris, pH 7.4, 10% 
glycerol, 50 mM NaCl, 0.2% Triton X-100, 0.5 mM Na3VO4 , 0.5 mM PMSF).  All wash 
buffer was removed and beads were resuspended in 25 µl of 4X LDS Loading Buffer 
(Thermo Fisher, Grand Island, NY) with 4 µl of 10X Bolt Sample Reducing Agent 
(Thermo Fisher), followed by Western Blotting.  Samples were boiled 5 min and run on 4-
12% Bis-Tris Plus gels (Thermo Fisher), followed by transfer to Immobilon-P 
polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA).  Membranes were 
blocked 1 h at room temperature in 3% bovine serum albumin (BSA) in Tris-buffered 
saline (TBS) containing 0.05% Tween-20 (TBS-T) followed by overnight incubation with 
pEphA/B (1:500) and EphA2 (Santa Cruz) (1:1000) primary antibodies.  Membranes were 
washed in TBS-T and incubated with goat anti-rabbit-HRP (1:5000) secondary antibody 1 
h at room temperature, followed by washing and developing with Luminol Reagent (Santa 
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Cruz).  Band intensities were quantified using Quantity One software (Bio-Rad, Hercules, 
CA).  
 
2.3.5 Internalization of EphA2. 
 
MDA-MB-231 cells were plated in 24-well plates on 10 mm square coverslips 
coated with 10 µg/ml fibronectin and incubated 24-48 h before treatment with 50 µM 
doxazosin and various doses of compound 27 (0.4, 2, 10, 50 µM) in 0.5% DMSO for 1 h.  
As another positive control, cells were treated with 2 µg/ml ephrin-A1-Fc.  Cells were 
then washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, PA) on ice for 10 min, followed by washing 
and permeabilization with 0.4% NP-40 for 10 min on ice.  Non-specific binding sites 
were blocked with 50 mM NH4Cl on ice for 10 min, followed by washing with PBS and 
0.1% BSA in PBS.  Cells were then incubated in primary mouse EphA2 antibody (D7, 
1:100) in 0.1% BSA/PBS for 1 h at room temperature, washed in PBS and BSA/PBS, 
followed by incubation in secondary donkey anti-mouse Alexa Fluor 488 antibody 
(1:300) in BSA/PBS for 30 min at room temperature.  Cells were washed in PBS and 
BSA/PBS, followed by mounting in DAPI Mounting Medium (Electron Microscopy 
Sciences). Images were taken with a Leica microscope.   
 
2.3.6 Docking investigation of compounds 24 and 27 
 
Docking studies were done to gain insight into the possible mode of interaction 
between the compounds and EphA2. The structures were drawn with Marvin Sketch 
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(www.ChemAxon.com) and energy minimized in MOE 2010 (www.chemcomp.com) 
using the MMFF94s force field. The database of compounds was then used for the 
docking studies. The protein crystal structure of 3FL7.pdb was prepared for docking by 
adjusting the pH of the system to a pH of 7.4 (6). The binding site in EphA2 was 
delineated by doxazosin. After docking, only the top docked pose of each compound was 
retained for analysis.  
 
2.3.7 Adrenoceptor binding activity of compounds 24 and 27 
 
Analysis of doxazosin and analog binding to rat 1a adrenergic receptor was 
performed by Eurofins Panlabs Taiwan, Ltd. (Taiwan).  [3H]-prazosin at 0.25 nM was 
used as the radioligand.  Compounds 24, 27, and doxazosin at 5 different doses ranging 
from 0.08 nM-3 µM in 0.1 % DMSO were incubated with [3H]-prazosin in a final volume 
of 1 ml of assay buffer (50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA) for 1 h at 25oC.  Non-
specific binding was defined by the use of 10 µM phentolamine.  Incubations were 
terminated by vacuum filtration over 0.1% PEI pretreated glass fiber filters and filters 
were washed for 10 s with ice cold 0.1M NaCl and the radioactivity retained on the filters 
was determined by liquid scintillation spectrometry.  The IC50 values were determined by 
a non-linear regression analysis using GraphPad Prism v.5 (GraphPad). 
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2.3.8 Pharmacokinetic studies with compound 27 
 
2.3.8.1     Preparation of stock and working solutions 
The stock solution of compound 27 and Prazosin (internal standard) were prepared by 
dissolving the corresponding compounds in DMSO to reach the concentration of 1 
mg/mL. One set of compound 27 working solutions at 20, 50, 100, 200, 500, 1000 and 
2000 ng/mL, was prepared by serial dilution of the stock solution with acetonitrile, and 
then used for preparing the calibration standards. Another set of compound 27 working 
solution at 10, 30, 250 and1600ng/mL was made in a similar way, and used for 
preparation of QC samples. The Prazosin working solution was prepared by diluting 1 
mg/mL stock solution to 100ng/mL with acetonitrile. 
2.3.8.2 Preparation of calibration standards and quality control (QC) 
samples 
The calibration standards were prepared by spiking 5 L of compound 27 working 
solution into 45 L blank mouse plasma to give the final concentration of compound 27 
at 2, 5, 10, 20, 50, 100 and 200 ng/mL. The QC samples were prepared in a similar 
manner at 1, 3, 25 and 160 ng/mL, representing LLOQ, LQC, MQC, and HQC of 
compound 27 in mouse plasma, respectively.  The same method was used for the mouse 
brain homogenate. All calibration standards and QC samples were further treated 
according to the sample preparation procedure.  
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2.3.8.3 Preparation of sample for analysis 
For unknown study samples, 45 Lof sample (serum or brain homogenate) was used 
and 5 L acetonitrile was added before extraction. Aliquots of 50 L mouse plasma or 
brain homogenate samples from the calibration standards, QC samples and 
pharmacokinetics study samples were mixed with 5 L internal standard working 
solution (100 ng/mL) and then vortexed for 10 s. 500 L of ethyl acetate was added to 
the samples, followed by vortexing for 60 s and then centrifuging at 12,000 rpm for 15 
min. Then 400 L of supernatant was separated and blow-dried using nitrogen blow 
down dry evaporator. The dry residue was reconstituted with 200 L acetonitrile/water 
(4:1, v/v) and then subjected to LC-MS/MS analysis.  
2.3.8.4 LC-MS/MS analysis 
The Shimadzu UPLC system (Columbia, MD) used consists of Prominence DGU-
20A3R inline degasser, two LC-30AD pumps, a SIL-30AC auto sampler, and a CBM-20A 
controller. The chromatographic separation was performed on a Kinetex C18 column (50 
× 2.1mm, 1.3m) with a SecurityGuard ULTRA Cartridge and UPLC in-line filter 
(Phenomenex, CA). An optimized gradient of mobile phase A: water with 2% acetonitrile 
and 0.1% formic acid and mobile phase B: acetonitrile with 0.1% formic acid at the flow 
rate of 0.25 ml/min was used (Table II).  
The detection of compound 27 was performed on an AB Sciex Qtrap 5500 mass 
spectrometer (Toronto, Canada) with positive electrospray ionization mode. The MRM 
function was used for quantification with the transitions setting at m/z 387.3→290.1 for 
compound 27 and m/z 384.1→247.1 for Prazosin. The optimized ion source parameters 
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were set as follows: ion spray voltage, 5000 V; temperature, 450℃; heating gas, 
nebulization gas, curtain gas, 40psi. Compound parameters were as follows: declustering 
potential, 141 V; entrance potential, 10 V; collision energy, 37 V for compound 27, 39 V 
for IS; collision exit potential, 24V for compound 27, 18V for internal standard. Data 
acquisition and quantification were performed using analyst software (version 1.6.2). 
2.3.8.5 Analytical method validation 
2.3.8.5.1  Calibration curve, sensitivity, and selectivity 
Calibration curves were constructed using the peak area ratio of compound 27 to IS 
Prazosin (y) vs. the concentration of compound 27 (x) in the calibration standards. The 
weighted linear regression was generated using 1/x as weighting factor. The sensitivity of 
the method was evaluated by whether the LLOQ, the lowest concentration in a calibration 
curve, can be quantified with accuracy and precision within 20%. The selectivity was 
evaluated by testing the presence of the interfering peak in blank plasma samples from 
six different sources and blank brain tissue with untreated mice.  
2.3.8.5.2  Matrix effect and extraction efficiency  
The relative matrix effect and extraction efficiency were studied at three QC levels: 3, 
25, and 160 ng/ml. The relative matrix effect was determined by comparing the peak area 
ratio of compound 27 and internal standard spiked in the blank plasma post-extraction 
solution with that in the neat solution (acetonitrile/water (4:1, v/v)). The post-extraction 
solution was prepared by blank plasma extraction and reconstitution of dry extracts with 
acetonitrile/water using the procedures described above. The relative extraction 
efficiency was determined by comparing the peak area ratio of compound 27 and internal 
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standard spiked in the plasma before extraction with that spiked in blank plasma post-
extraction solution. The same procedure was repeated for brain homogenate. 
2.3.8.5.3  Precision and accuracy 
Intra- and inter-assay precision and accuracy were assessed using QC samples at three 
different concentrations: 3, 25, and 160 ng/ml. Intra-assays were carried out with five 
replicates (n=5) for each concentration in the same day, while inter-assay were performed 
for each concentration in five replicates in five days. The experimental determined 
concentrations of compound 27 in QC samples were compared to the theoretical spiked 
values.  
2.3.8.5.4  Stability study 
The stability of compound 27 in mouse plasma was evaluated by subjecting QC 
samples (3 and 160 ng/ml) to the following conditions: sitting at room temperature for 6 
and 24h, three freeze/thaw cycles, -20℃ for 2 months. The freeze/thaw cycle comprises 
freezing for 24h at -20℃ and then thawing at room temperature for 30 min.  
2.3.8.6 Pharmacokinetic studies of compound 27 in mouse plasma and brain 
tissue 
The animal study was approved by Case Western Reserve University animal care and 
use committee and adheres to the Guide for the Care and Use of Laboratory Animals, 8th 
edition (NIH). Three-month-old female mice (Charles River) were randomly divided to 
14 groups (5 mice per group). The mice were treated with the compounds or vehicle via 
subcutaneous injection or intraperitoneal injection (two sets of different treatment). At 
different time points ranging from 30 mins to 24 h, the mice were anesthetized to perform 
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the heart perfusion with saline, and then euthanized. 200 L of blood sample was 
collected from each mice and brain tissue was collected as well. The plasma was 
immediately separated by centrifugation at 5000 rpm for 5 min at room temperature and 
stored frozen at −20 ℃ until analysis. The brain tissue was homogenized and centrifuged 
at 10,000 rpm to collect the supernatant, and then stored frozen at −20 ℃ until analysis. 
The feasibility of the developed quantitative method was tested through a 
pharmacokinetic study of compound 27 in mouse plasma and brain tissue.  
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CHAPTER III 
 
COPALIC ACID ANALOGS AS PROSTATE CANCER THERAPEUTICS 
   
3.1 INTRODUCTION 
 
 Prostate cancer is the most common type of cancer among men and the second 
leading cause of cancer related deaths in the US (11). The cancer (uncontrollable growth 
of cells) begins in the prostate gland and may eventually metastasize (spread throughout 
the body). Some of the risk factors that are associated with prostate cancer are age, 
ethnicity, family history, and geography (9). There are also other factors that may play a 
role such as diet, smoking, exposure to chemicals, obesity, inflammation of the prostate, 
and sexually transmitted infections, however it is unclear if they are significant (9). There 
are different stages of prostate cancer that are categorized based on the size of the 
primary tumor, whether the cancer has spread to the lymph nodes, whether the cancer has 
metastasized, PSA level in the bloodstream, and the Gleason score which is a measure of 
the probability of how likely it is for the cancer to grow rapidly (9).
There are screening tests for early detection, such as the PSA test where elevated 
PSA levels suggests the development of prostate cancer, and digital rectal exam (DRE) 
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(9). Currently, several treatment options are available: radiation therapy, cryotherapy, 
chemotherapy, and bone-directed therapy are some common treatment procedures used 
for any type of cancer, whereas surgery, and hormone therapy are based on lowering the 
levels of androgens and androgen receptor, which play a key role in the functioning of the 
prostate (9). Although they may be successful, most patients eventually develop 
resistance to these treatments. Because of this, there is a great need for a new therapeutic 
agent that can overcome resistance and provide patients with a better prognosis. 
 Androgen receptor belongs to the steroid and nuclear receptor superfamily and is 
involved in processes that are responsible for male sexual differentiation (3). The ligands 
that bind to AR are known as androgens, which can be steroidal or nonsteroidal and 
agonists or antagonists based on their structure and the ability to promote or inhibit gene 
transcription, respectively (3). The most common ones with the highest affinity for AR 
are testosterone and 5-dihydrotestosterone. AR mainly exists in the cytoplasm stabilized 
by various heat shock proteins (3). When a ligand binds, the heat shock proteins 
dissociate, and AR is transported to the nucleus by importin- which is a nuclear 
transport receptor. The DNA binding domain of AR binds to the promotor region of the 
DNA and recruits transcriptional factors and other co-regulators (whether they are co-
activators or co-repressors) in order to begin transcription (7).  
 Because of its involvement in male physiological differentiation and functions, 
AR also has implications in prostate cancer. Elevated androgens and AR receptor levels 
have shown to promote prostate cancer cell survival and proliferation. Accordingly, many 
therapeutic agents and/or procedures’ purpose is to decrease the level of androgens. Even 
though these treatments are partially successful, patients ultimately develop resistance 
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which has become a major concern. Especially in CRPC, although the level of androgens 
is low, AR is able to continue its functions in an androgen independent manner (2). This 
suggests that there is another mechanism by which AR is able to remain stable and 
function.   
Heat shock protein 27 kDa is another protein that has implications in prostate 
cancer. And in this project, we focus on this protein mainly because AR is a client protein 
of HSP27 where it is involved in stabilizing and chaperoning activities. HSP27 is a small 
chaperone protein that is involved in stress induced cellular functions. Mainly known for 
their chaperoning function, HSP27 is also involved in the inhibition of apoptosis, 
protection against oxidative stress, and regulation of the cytoskeleton (12). Although 
HSP27’s ability to refold denatured proteins remain doubtful, it is involved in leading 
misfolded proteins to proteasomal degradation (1). This process of managing the level of 
denatured protein may be one way that HSP27 regulates cell death (3). Following stress, 
HSP27 is speculated to inhibit apoptosis by interfering in both the upstream and 
downstream mechanisms of cytochrome c release from the mitochondria (8). HSP27 is 
also involved in regulating the cytoskeleton by promoting actin polymerization. 
Moreover, it is able to lower the level of reactive oxygen species during oxidative stress 
(4).  
The overexpression of AR seen in CRPC helps promote the cancer cells’ growth 
and survival even when the level of androgens is low and eventually leads to resistance. 
Antagonists of AR may not be an effective therapeutic strategy since resistance may be 
developed due to mutations in AR at a genomic and/or protein level. Therefore, 
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degradation of AR indirectly through the inhibition of HSP27 is a viable approach to 
obstructing cancer cell growth because of HSP27’s involvement in AR’s stability.  
Copalic acid, which is a diterpenic acid in copaiba oil, has recently been 
discovered to inhibit HSP27. Copaiba oil which is native to South America and Africa 
has been a folk medicine since the 19th century (10). It has anti-inflammatory, 
antimicrobial, and antinociceptive properties (6). Copaiba oil which comes from the 
Copeifera multijuga species has shown to inhibit tumor growth as well. This activity is 
due the diterpenic acids that are present in copaiba oil, such as copalic acid (6). The 
association of HSP27 with AR’s stability and the inhibition of HSP27 by copalic acid 
suggest that it can be used as a therapeutic agent for the treatment of prostate cancer. 
Therefore, in this project we generate new compounds using copalic acid as a lead 
compound in order to increase potency in inhibiting HSP27 and in turn reduce the level 
of AR in prostate cancer cells.  
 
3.2 RESULTS AND DISCUSSION 
 
3.2.1 Several copalic acid analogs showed better activity in degrading AR 
 
 In prostate cancer, AR plays a major role because of its involvement in cell 
differentiation and proliferation. In the cytoplasm, AR is stabilized by small chaperone 
proteins, such as HSP27, which has also been known to have implications in prostate 
cancer. In this study, we speculate that our compounds may inhibit HSP27 which would 
cause the down regulation of AR.  We synthesized 15 analogs of copalic acid with  
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Figure 3.1: Synthesis and structures of the copalic acid analogs. 
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different moieties at the carboxyl group (Figure 3.1). These were then evaluated for their 
activity to down- regulate AR in LNCaP cells by western blot. The results demonstrated 
that, in general, modifying the carboxylic acid moiety in the copalic acid increased the 
activity of the analogs. At 20 M, compounds 3, 5, 12, and 13 displayed moderate 
activity in decreasing the level of AR which is comparatively better than copalic acid (3.2 
A). On the other hand, compounds 4 and 7 seem to eradicate all the AR in the LNCaP 
cells at 20 M. Considering the structures, these data suggest that the aromatic moiety 
that was substituted in place of the carboxylic acid group may be responsible for this 
activity. The carboxylic acid moiety is ionized into carboxylate ion in the cell culture 
medium and this generated negative charge limits the ability of copalic acid to penetrate 
the cell membrane. Therefore, it is possible that converting the carboxylic moiety may 
enhance permeation of the compounds into the cells. It is also likely that changes in 
hydrophobicity contributed to the increased activity since it would have the ability to pass 
through the hydrophobic cell membrane more easily. Comparing compounds 4 and 15, 
which have the same 4-methoxybenzyl group but a different linking bond, it may be 
speculated that the nitrogen atom in the amide group of compound 4 which does not 
allow rotation may be preferred over the ether bond of compound 15 which allows 
rotation. 
Even though compound 4 and 7 showed improved activity, their aromatic 
structure is not sufficient to provide information to summarize what type of substituents 
on the phenyl ring is capable of improving activity. Different moieties result in different 
interactions when binding to the active site, such as hydrogen bonding, Van der Waals  
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Figure 3.2: (A)Western blot analysis of all 15 copalic acid analogs; (B) Dose-dependent 
activity of compound 4; (C) Dose-dependent activity of compound 7  
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forces, or ionic bonding, which may lead to stronger or weaker interactions compared to 
the lead compound. In order to determine which compound’s moiety results in stronger 
interactions and therefore has higher activity a dose-dependent experiment was carried 
out to further examine the two analogs. In the cell viability assay, compound 4 showed 
the most activity in dramatically decreasing the level of AR in LNCaP cells at 5 M 
(Figure 3.2 B). Compound 7 only showed a decrease in the level of AR starting at 20 M 
(Figure 3.2 C). Compound 4 has the 4-methoxybenzyl group and compound 7 consists of 
benzonitrile group which are both electron donating groups. However, more compounds 
need to be synthesized and analyzed in order to summarize the structure activity 
relationship. The IC50 values of compounds 4 and 7 were calculated to be 1.73 ± 0.72 M 
and 4.81 ± 0.92 M, respectively, which suggests that both of these have the potential to 
be the hit compounds for further development of therapeutic agents to treat prostate 
cancer (Figure 3.3).  
 
3.3.2 Inhibition of chaperone function 
 
Consequently, the chaperone inhibition function of the compounds was 
investigated with an in vitro chaperone assay.  HSP27 is a protein that is involved in 
many cellular protective functions, the most prevalent being chaperone function. In the 
prostate cells, HSP27 is involved in stabilizing AR in the cytoplasm. Compounds 4 and 7 
were evaluated for their potency to inhibit chaperone function. Dithiothreitol (DTT) 
induced insulin aggregation can be stabilized by -crystallin. The latter is a protein that 
shares a common functional feature, -crystallin domain, with HSP27 which is  
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Figure 3.3: LNCaP cell growth inhibition by compounds 4 and 7. 
 
  
 
 
 
 
 
99 
 
responsible for the mediation of the assembly of oligomers and the chaperone functions 
of both -crystallin and HSP27. Furthermore, the three-dimensional structures of -
crystallin and HSP27 overlap which suggests that both proteins may be inhibited by 
similar inhibitors. The -crystallin stabilized DTT induced insulin precipitation 
chaperone function was inhibited by copalic acid in our previous study. The kinetics of 
this phenomenon was monitored in the absence of -crystallin, or in the presence of -
crystallin with or without the analogs. Similar to copalic acid, compounds 4 and 7 also 
demonstrated inhibition of the -crystallin chaperone function. Both compounds showed 
the same level of inhibition at a concentration of 10 M. These results suggest that these 
two compounds are small chaperone inhibitors as well (Figure 3.4). Both showed better 
potency in down regulating AR and inhibiting prostate cancer cell growth compared to 
the lead compound copalic acid.  
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Chemistry 
 
 Crude copaiba oil was obtained from Natural Joint Solutions Inc. (FL). Chemicals 
and solvents were used as received without further purification. Thin-layer 
chromatography was performed on silica gel TLC plates with fluorescence indicator 254 
nm (Fluka). Flash column chromatography was performed using silica gel 60Å (BDH, 
40-63 µM). Mass spectra were obtained from the Bruker ion-trap mass spectrometer at 
Cleveland State University MS facility center. All NMR spectra were recorded on a  
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Figure 3.4: -Crystallin lost the activity to prevent DTT induced insulin aggregation in 
the presence of compound 4 or compound 7. 
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Bruker 400 MHz (13C NMR at 100 MHz) using DMSO-d6 as the solvent. Chemical shift 
(δ) for 1H NMR spectra were reported in parts per million to residual solvent protons.  
 
3.3.2 Chemical Synthesis of copalic acid analogs 
 
The following summarized procedure was followed for the isolation of copalic 
acid (Detailed procedure described in previous study). Crude copaiba oil that was 
manufactured by Natural Joint Solutions, Inc. was used for the extraction of copalic acid. 
The aqueous layer, after extracting the crude copaiba oil in ethyl ether with aqueous 
potassium hydroxide, was neutralized with hydrochloric acid. After extracting the organic 
layer with ethyl ether, it was washed with water, dried with anhydrous sodium sulfate, 
and concentrated under vacuum. This fraction was subjected to column chromatography 
using gradient elution with different ratios of hexane and/or ethyl acetate to give seven 
sub fractions. The sub fraction that contained copalic acid was stirred at room 
temperature with 4-methoxyphenol and dicyclohexyl carbodiimide in dichloromethane. 
After filtration, the filtrate was concentrated under vacuum and purified by column 
chromatography. The 4-methoxyphenol ester of copalic acid that was obtained was 
neutralized by hydrochloric acid and extracted by ethyl acetate. The organic layer that 
was concentrated under vacuum followed by column chromatography purification 
produced about 500 mg of copalic acid (5).  
Following the extraction of copalic acid, the carboxylic acid moiety was modified 
into either an amide or ester analog via a one-step reaction. Generally, the reactions were 
carried out at room temperature using dichloromethane (DCM) as the solvent. About 30 
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mg (0.1 mmol) of copalic acid was stirred with 62 mg (0.3 mmol) of 
dicyclohexylcarbodiimide (DCC) and 0.15 mmol of the aromatic amine or the phenol 
until copalic acid was entirely consumed. Then the insoluble solid was filtered and 
washed with CH2Cl2, followed by concentration under vacuum and purification by 
column chromatography to yield the product. Chemical synthesis was carried out to 
generate 15 copalic acid analogs and their structures and purity were verified though 
NMR analysis and LC-MS, respectively. 
 
3.3.3 Cell Culture and antibodies 
 
  Prostate cancer cell line, LNCaP, was obtained from ATCC (Rockville, MD). 
Cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 2mmol/L L-
glutamine, 1 mmol/L sodium pyruvate, 2% penicillin-streptomycin, and ciprofloxacin. 
FBS was heat inactivated for 30 min in a 56°C water bath before use. Cell culture was 
grown at 37°C, in a humidified atmosphere at 5% CO2 in a VWR CO2 incubator 
(Bridgeport, NJ). 
Antibodies used included rabbit polyclonal antibody against androgen receptor 
and -actin (Cell Signaling).  Secondary antibody used was anti-rabbit conjugated to 
HRP (Cell Signaling).  
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3.3.4 Western Blot 
 
 LNCaP cells were treated with DMSO (as the negative control), copalic acid (as 
the positive control), and the 15 analogs for 48 h. The concentration of copalic acid used 
was 200 M since 20M copalic acid did not show any activity. The cells were lysed, 
briefly sonicated and centrifuged at 16,000 x g for 50 min. Then 30 g of protein was 
boiled with 2X loading buffer for 5 min, electrophoresed on a 10% SDS-polyacrylimide 
gel, and transferred onto a nitrocellulose membrane. The membrane was blocked for 1 h 
with 5% nonfat milk in PBST followed by incubation with AR primary antibody. After 
washing, the membrane was incubated with horseradish-conjugated secondary antibody. 
The bands were visualized by chemiluminescence with ECL reagent (Thermo Scientific). 
 
3.3.5 Cell viability analysis 
 
 The effects of select copalic acid analogs on LNCaP cell proliferation were 
analyzed using MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide). A 96-well, flat bottomed plate was seeded with 6000 LNCaP cells per well 
using RPMI 1641 medium for 24 h. Next, the cells were treated with varying 
concentrations of the compounds dissolved in DMSO (final concentration ≤0.1%) in 
medium for 72 h. Controls received DMSO at a concentration equal to that of the cells 
treated with the compounds. The medium was removed and replaced with 120 L of 0.5 
mg/mL MTT reagent in fresh medium and cells were incubated in the CO2 incubator at 
37°C for 1h. The supernatant was removed from the wells and replaced with 200 L of 
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DMSO in order to solubilize the reduced MTT dye. Absorbance was measured at 570 nm 
using Spectramax plate reader.  
 
3.3.6 Anti-Chaperone Assay 
 
3.3.6.1 Endpoint measurement 
 A mixture of 0.24 mg/mL human recombinant insulin, 150 g/mL -crystallin, 
and compounds 4 and 7 in 98 L of sodium phosphate buffer, pH 7.4, was incubated at 
37°C for 5 min. Then 2 L of 1M DTT in water was added to initiate insulin aggregation. 
The absorbance (A) at 400 nm was recorded after 45 min incubation at 37°C in a plate 
reader. A mixture of 0.24 mg/mL insulin in the absence or presence of 150 g/mL -
crystallin with DMSO was used as a control. For the evaluation of the effects of the 
compounds 4 and 7 on DTT-induced insulin aggregation, a mixture of 0.24 mg/mL 
insulin and 20 mM DTT in the presence of DMSO or compound 4 or compound 7 was 
incubated for 45 min at 37°C followed by the measurement of the absorbance at 400 nm.  
3.3.6.2 Kinetic measurement 
 A mixture of 0.24 mg/mL human recombinant insulin, 150 g/mL -crystallin, 
and compounds 4 and 7 in 98 L of sodium phosphate buffer, pH 7.4, was incubated at 
37°C for 5 min. Then 2 L of 1M DTT in water was added to initiate insulin aggregation. 
The absorbance at 400 nm was recorded after 45 min incubation at 37°C in a plate reader. 
A mixture of 0.24 mg/mL insulin in the absence or presence of 150 g/mL -crystallin 
with DMSO was used as a control. The -crystallin inhibition potency (%) of compounds 
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at 45 min was determined by A(-crystallin+compound+DTT) −A(−crystallin+DTT) /ADTT – 
A(−crystallin+DTT), where A(-crystallin+compound+DTT) −A(−crystallin+DTT) represents an increase of 
insulin aggregation level in the presence of -crystallin without the compounds while 
ADTT – A(−crystallin+DTT) represents a decrease in insulin aggregation level used by -
crystallin.  
 For the evaluation of HSP27 inhibition potency of compounds 4 and 7 the same 
procedure was followed with the exception of using HSP27 instead of -crystallin. The 
final concentration of HSP27 in the assay was 15 g/mL. 
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